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SUMMARY 
 
Muscular dystrophies are a group of genetic diseases showing muscle degeneration 
characterized by progressive skeletal muscle weakness, defects in muscle proteins fiber 
necrosis, and progressive substitution of fibers with connective and adipose tissue. 
The therapeutic protocols currently in use, based on corticosteroid administration, provide 
some delay in the progression of the disease, but they are associated with severe side 
effects. The genetic approaches (exon skipping and antisense oligonucleotides) currently 
being investigated show some degree of success, however they are directed to specific 
subsets of population and cannot restore fully the damage already caused by the disease to 
the muscle. 
Several studies had demonstrate that the pathophysiology of muscular dystrophies 
correlates with an altered synthesis of nitric oxide (NO), in fact neuronal nitric oxide 
synthase (nNOS) is absent from the sarcolemma and relocated to the cytosol, with total 
muscle NOS activity being thus reduced. 
During the years, nitric oxide donors were identified as good candidate molecules for 
Duchenne Muscular dystrophy therapy and recently, our group found that a NO donor, 
molsidomine, is able to slow disease progression and to restore the functional capacity of 
damaged muscle, significantly enhancing spontaneous and forced motor activities1. Nitric 
oxide regulates some mitochondrial functions, such as morphology and complexes 
activity; moreover mitochondrial dysfunction has long been suspected to be an important 
pathogenetic feature in muscular dystrophies even if their role is not fully understood. 
The aim of this project is to analyze the mitochondrial profile of alpha-Sarcoglican (a-SG) 
null mice, a mouse model for Limb Girdle muscular dystrophy 2D (LGMD 2D) and to 
evaluate a possible effect of molsidomine on mitochondrial function. Our long term aim 
is to define approaches that limit muscle wasting, with a dual finality, on the one hand to 
ameliorate the dystrophic symptoms per se, on the other to increase the efficiency of 
cell/gene therapies, in a combined therapy for the disease. To this end elucidation of 
novel possible targets is necessary and this is the final goal of this project. 
We find out a severe reduction in mitochondrial content in both tibialis anterior and 
diaphragm accounting for a lower OxPhos capacity of these muscles. The respiratory 
rates relative to mitochondrial DNA suggest that mitochondrial content is the major 
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determinant of the lower oxidative capacity of a-SG null muscles. The low mitochondrial 
content in dystophyc mice is due to a persistent inhibition of the mitochondrial biogenesis 
pathway. Unexpectedly, the treatment with the NO-donor molsidomine is not able to 
restore mitochondrial content in a-SG-/- mice, but it is able to improve significantly their 
oxidative capacity, triggering a therapeutic fiber switch and stimulating fatty acid 
oxidation rather than improving mitochondrial function per se. Molsidomine promotes in 
fact an important deacetylation and activation of peroxisome proliferator-activated 
receptor γ coactivator 1-gene α (PGC-1α), the principal trascriptional co-activator 
involved in muscle fiber type determination. Deacetylation of PGC-1α occurs through a 
nitric oxide-dependent AMP activated protein kinase (APMK) activation leading to an 
increase expression and activity of the deacetylase Sirt1. 
Altogether these results highlight for the first time a defective mitochondrial biogenesis in 
LGMD 2D impairing mitochondrial metabolism and define the increase in OxPhos 
capacity associated with fiber switch as rescue mechanism with a mechanism independent 
on mitochondrial biogenesis but focused on lipid metabolism.  
Introduction 
 
 
INTRODUCTION 
Chapter 1: Muscular dystrophies 
 
Muscular dystrophies are a clinically, genetically, and biochemically heterogeneous group 
of genetic disorders affecting primarily the skeletal muscle 2. They are characterized by 
progressive muscle weakness that affects limb, axial, and facial muscles with different 
severity. In some specific forms, also other muscles can be affected such as respiratory 
muscles, cardiac smooth muscles, and swallowing muscles. In rare variants, the disorder 
is associated with the damage of other organs or tissues, including brain, eyes, inner ear 
and skin. There is a high degree of variability between different forms of muscular 
dystrophy, in terms of severity, age of onset, rate of progression and prognosis. 
In the past two decades a better knowledge of the mechanisms underlying muscular 
dystrophies, the important improvements in standards of care and new therapeutic 
approaches have changed both the natural history and long-term perspectives of these 
disorders. The progression of genetic analyses has also resulted in an unexpected 
expansion of the clinical range of mutations associated with the disease, including allelic 
disorders that share no features with the first muscular dystrophy described 3-4. The 
availability of clinical guidelines based on expert consensus ameliorated the standards of 
cares, the prevention and the management of complications, and definitely the clinical 
course and the survival of patients. Finally, better knowledge about the molecular basis of 
these disorders led to the development of new treatment approaches, several of which are 
already in clinical trials 5.  
The most common and extensively studied muscular dystrophies are those involving 
mutations of the dystrophin-dystroglycan-laminin network 6, (Table 1). The organization 
of the dystrophin complex at the sarcolemmal level of muscle fibers is shown in Figure 1 
and demonstrates the pivotal role of dystrophin for muscle stability, since it provides a 
mechanical  link between the internal cytoskeleton and the extracellular matrix. The 
dystrophin-associated proteins include dystroglycan, sarcoglycan, and cytoplasmic 
(syntrophin) subcomplexes. The dystroglycan complex is formed by of α-dystroglycan, 
which associates with the basal-lamina protein merosin in the extracellular matrix, and β-
dystroglycan, a transsarcolemmal protein that binds α-dystroglycan and dystrophin. The 
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SG complex includes four trans-sarcolemmal proteins (α-, β-, γ and δ-SG) that associate 
each other and  function as a single unit, with δ-SG serving as the link to β-dystroglycan 
of the dystroglycan complex. Within the cytoplasmic subcomplex, the COOH-terminal 
region of dystrophin is bound to syntrophin, whereas the amino-terminus of dystrophin 
binds F-actin. 
 
 
 
Figure 1: The dystrophin-associated protein complex 
 
 
Mutations of dystrophin gene are the most common cause of muscular dystrophy 
accounting for Duchenne and Becker muscular dystrophies, both X-linked, recessively 
inherited disorders. In terms of incidence, together with Duchenne Muscular Dystrophy 
(DMD), particularly relevant is also the Limb girdle Muscular Dystrophy 2D (LGMD-
2D) characterized by the lack of alpha sarcoglycan (a-SG) in the dystrophin-sarcoglycan 
complex which also leads to muscle degeneration. These two forms share some 
similarities in how skeletal muscle undergoes degeneration.  
Skeletal muscle of dystrophic patients is more susceptible to eccentric contraction-
induced injury than the healthy one. In response to this type of injury, damaged muscle 
fibers undergo repeated cycles of necrosis and regeneration, during which satellite cells, 
the primary myogenic precursor cells, become activated to regenerate muscle fibers. 
However, the regenerative process is largely inefficient and results in fibrotic changes and 
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fatty deposition in skeletal muscle and the most severely affected skeletal muscle is the 
diaphragm.  
At present there is no satisfactory therapy for this pathology, apart for the treatment with 
corticosteroids that, however, provides only temporary improvements and is associated 
with severe side effects. The genetic approaches (exon skipping and antisense 
oligonucleotides) currently being investigated show some degree of success, although 
they are directed to specific subsets of population and cannot restore fully the damage 
already caused by the disease to the muscle.  
 
 
 
Table 1: Genes associate with selected muscular dystrophies 6 
 
 
                        
1.1 Classification and epidemiology 
 
For many years, muscular dystrophies have been classified in accordance to the main 
clinical manifestations and age of onset (limb girdle muscular dystrophies, Emery-
Dreifuss muscular dystrophy, and congenital muscular dystrophies). Furthermore, the 
heterogeneous groups such as limb girdle muscular dystrophies or congenital muscular 
dystrophies were sub-classified according to their inheritance and the genetic defect 
responsible for the individual forms (LGMD1A, LGMD1B, LGMD2A, and LGMD2B), 
where the number 1 indicated the dominant inheritance whereas the number 2 the 
7 
 
Introduction 
 
 
recessively inherited disorders. The letters A, B, and C indentified the different genes 
involved. The improved understanding of the mechanisms underlying these forms 
provided new clues about their classification that cannot be based only on the previous 
assumption that every clinical phenotype is related to a distinct genetic defect. The old 
classification, based on the clinical findings, is now always accompanied by information 
about the primary protein defect and their localization and function as shown in Table 2 5. 
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Table 2: Classification of muscular dystrophies 5 
 
 
Duchenne muscular dystrophy is the most common inherited muscle disease of 
childhood, with an estimated prevalence in northern England of 8.29 per 100 000 boys; a 
milder allelic variant, Becker muscular dystrophy, has a slightly lower prevalence of 7.29 
per 100 000 boys. Myotonic dystrophy is the most common form in adults, with an 
estimated prevalence of 10.6 per 100 000 men, followed by facioscapulohumeral 
muscular dystrophy (FSH), with an estimated prevalence of three per 100 000 men 7. 
Between limb girdle muscular dystrophies, the recessive forms are more common than the 
dominant ones and limb girdle muscular dystrophy 2A seems to be more prevalent in 
southern Europe, whereas limb girdle muscular dystrophy 2I is more diffuse in northern 
Europe, followed by limb girdle muscular dystrophy 2B 8-9.  
Geographic regions seem to play an important role in terms of frequencies also in some 
particular forms of congenital muscular dystrophy such as Fukuyama congenital muscular 
dystrophy, that is the most common form of congenital muscular dystrophy in Japan and 
is caused by a founder recessive mutation 10. 
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1.2 Clinical manifestations 
 
The molecular heterogeneity of muscular dystrophies is accompanied by great variability 
in terms of clinical manifestation and age of onset that can change from birth or childhood 
to adulthood.  
In general, congenital muscular dystrophies have evident clinical signs at birth or in the 
first few months of life, however other dystophies, such as Duchenne muscular dystrophy 
or some forms of the limb girdle muscular dystrophies, show clinical sign during early or 
late childhood when independent ambulation has been achieved. Finally, other limb girdle 
muscular myotonic dystrophy and facioscapulohumeral muscular dystrophies do not 
appear until adulthood. The common feature of these different forms of pathologies is 
definitely the marked skeletal muscle weakness with a different distribution that can be a 
useful tool to distinguish between different variants. (Figure 2) 2. 
In several forms, the peculiar distribution of weakness allows the disorder to be identified 
rapidly, as is the case of FSH and oculopharyngeal muscular dystrophy. Moreover often 
muscle weakness is associated with either muscle atrophy or relative hypertrophy, as seen 
in Duchenne muscular dystrophy, Becker muscular dystrophy, and several limb girdle 
muscular dystrophies. Myotonic dystrophy is unique because it is associated with 
stiffness of various muscles (and difficulties in relaxation of grip), a phenomenon known 
as myotonia. Progressive rigidity of the elbow, Achilles tendon, and spine almost 
invariably occurs in Emery-Dreifuss muscular dystrophy and in Ullrich congenital 
muscular dystrophy, but is less common in limb girdle muscular dystrophy 2A and is rare 
in other variants 5. 
In general the progression of the disease is very variable and is mainly controlled by the 
severity of the individual mutation affecting each gene. In most patients affected by 
congenital muscular dystrophy variants, ambulation is never achieved; in DMD and 
LGMD ambulation is achieved but it will be lost with the progression of the diseases, 
indeed children become progressively weaker by the end of the first decade, and they lose 
the ambulation about in the early or middle teenage years and they are oblige to use 
whellchair. In the other forms of limb girdle muscular dystrophies and in most cases of 
facioscapulohumeral muscular dystrophy, ambulation can be maintained and wheelchair 
assistance is needed only later in life. Clinical severity of myotonic dystrophy is 
extremely variable, ranging from fatal outcome to minimally affected adults with only 
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cataracts and grip myotonia. Respiratory impairment is frequent and its severity is not 
always related to the degree of motor impairment. In most muscular dystrophies in which 
this complication occurs, respiratory insufficiency happens only after loss of ambulation 
as a result of generalized weakness of inspiratory and expiratory muscles. In other forms, 
this manifestation is the result of selective diaphragmatic weakness. 
 
 
 
Figure 2: Distribution of predominant muscle weakness in different types of dystrophy. 
A, Duchenne-type and Becker-type; B, Emery-Dreifuss; C, limb-girdle; D, facioscapulohumeral; 
E, distal, F, oculopharyngeal. 2. 
 
 
Respiratory insufficiency typically starts at night, resulting in disturbed sleep, morning 
drowsiness and headaches, loss of appetite, and frequent chest infections.  
Cardiac involvement is common in many muscular dystrophies, but is not a consistent 
finding 11-12.  Age of onset, progression, and type of cardiac involvement are variable. 
Although in DMD and some LGMD dilated cardiomyopathy is the main presenting 
cardiac concern, in others, such as Emery-Dreifuss muscular dystrophy, conduction 
defects are a severe and consistent feature 13.  
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In some congenital muscular dystrophies and rarely in some LGMD, functional or 
structural brain damage occurs. Example of functional deficiency are present in DMD and 
in myotonic dystrophy 14, in particular in Duchenne muscular dystrophy, a third of boys 
have non-progressive mental retardation and behavioral or psychiatric comorbidities (eg, 
attention deficit disorder or autism) 15. Structural brain defects have also been recorded in 
the advanced stages of DMD and of myotonic dystrophy. 
 
 
 
1.3 Limb–Girdle Muscular Dystrophies 
 
Limb-girdle muscular dystrophy describes a heterogeneous group of muscle disorders 
characterized by the predominantly proximal distribution of limb–girdle weakness. For 
decades, the LGMD diagnosis was an exclusionary one: when Duchenne muscular 
dystrophy (DMD)/Becker muscular dystrophy, FSH, myotonic dystrophy, metabolic 
myopathies, and other syndromic disorders were ruled out, the patient was assigned an 
LGMD diagnosis. Their current classification based on inheritance pattern, comes from 
the discovery of genetically distinct subtypes of LGMD and the most common forms are 
the autosomal recessive disorders, called LGMD2 (2A–2I), whereas less diffuse are the 
autosomal dominant forms called LGMD1 with subtypes (1A-1E) 16.  
The autosomal-recessive LGMDs are a heterogeneous group of muscular diseases 
characterized by progressive muscle weakness and, in severe cases, death in the second or 
third decade of life 17. The more severe phenotypes are often caused by mutations in the 
SG genes α (LGMD-2D), β (LGMD-2E), γ (LGMD-2F), and δ (LGMD-2C). The 
sarcoglycan complex stabilizes the association  between dystrophin, dystroglycan and the 
extracellular matrix  maintaining the mechanical stability of the plasma membrane during 
muscle contraction. Sarcoglycanopathies mimic dystrophinopathies, often with an early 
onset and with the development of muscle hypertrophy, although cognitive deficit is rare. 
A primary deficiency of any single SG leads to partial or complete absence of all other 
sarcoglycans on the sarcolemma, suggesting that sarcoglycans are mutually dependent on 
each other 18. Phenotypically, the SG deficiencies are indistinguishable from the 
dystrophin deficiencies 19, but if dystrophinopathies show secondary deficiencies of all 
SG proteins, sarcoglycanopathies usually show normal levels of dystrophin.  
12 
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Accordingly, LGMDs represent an important group of muscular dystrophies, widely used 
to investigate the dystrophic muscular damage and for this reason different mouse models 
with mutations in sarcoglycans genes have been generated. In particular α-SG-deficient 
null mutant transgenic mice have been generated targeting the disruption of the α-SG 
gene 20. These mice show the complete absence of α-SG transcript and protein, a 
complete loss of the SG complex and sarcospan, and develop a progressive muscular 
dystrophy similar to its human homologue, LGMD-2D.  
In contrast to mdx mouse, the murine model of DMD, a-SG null mice show persistent 
muscle necrosis progressive with age, which is an important hallmark of the human 
disease. Moreover these mice demonstrate significant muscle hypertrophy and muscle-
specific changes in contractile properties. Taken together this mouse model is suitable for 
elucidating the pathogenesis of limb-girdle muscular dystrophies and for the development 
of therapeutic strategies for this disease. 
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Chapter 2: Therapeutic approaches to muscular dystrophy 
2.1 Current treatments 
 
The lack or alteration of structural proteins, such as dystophyn or sarcoglycan proteins, 
into the musculoskeletal system results in a chronic influx of calcium into the myofibers, 
causing cellular death and inflammatory responses. For this reason corticosteroids have 
been proposed as a pharmacological therapy for dystrophinopathies, in order to counteract 
muscle necrosis, inflammation and to reduce the muscle membrane susceptibility to 
damage. At the moment, although there are no specific cures for the different forms of 
muscular dystrophy, corticosteroid administration represents the therapeutic protocol 
currently in use for DMD and other types of muscular dystrophy improving quality of life 
and extending lifespan 21. 
After preclinical studies, the unequivocal proof of efficacy of glucocorticoids was 
established in a randomized, double-blind controlled trial in DMD patients 22. At six 
months prednisone treatment compared to placebo improved muscle strength and 
pulmonary functions, as well as the time needed to rise from supine to standing, to walk 9 
m, and to climb four stairs (p < 0.001 for all comparisons). Some years later, similar 
results were documented using deflazacort, an alternative, sodium-sparing glucocorticoid 
that was shown to prolong ambulation (p < 0.005) 23. Furthermore, a recent blind placebo-
controlled study demonstrated that a high-dose administered by a weekend regimen of 
prednisone (10 mg/kg/wk divided over 2 days) produced fewer side effects compared to 
standard daily dosing while retaining the benefits that were observed with daily 
prednisone for DMD 24. 
In general the corticosteirod treatments provide some delay in the progression of the 
disease, but they are associated with severe side effects, such as weight gain with a 
cushingoid appearance. DMD boys on steroids are also at risk of hypertension, cataract 
formation, loss of bone density, vertebral compression fractures, and long bone fractures. 
Long-term administration may be limited in some cases by steroid-induced behavioral 
problems frequently observed with this class of drugs 25. 
Also for the large majority of LGMD patients, there are no decisive therapies and 
treatments remain palliative and supportive. The management of the disease involves 
physiotherapy to prevent joint deformities and promote walking, further passive 
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stretching should be instituted early, soon after diagnosis both in LGMD and DMD. With 
regard to lower limb surgery, which has been studied more in the DMD population, 
bilateral hip and knee replacement, aponeurectomy of the iliotibial band, or Achilles 
tendon lengthening may prolong ambulation, but these procedures remain controversial. 
Surgery may prolong assisted standing ability and, in turn, prevent long-term spine 
deformities and back pain. Considering cardiomyopathy or conduction defects often 
developed by patient, heart monitoring is very important. Although specific guidelines for 
each type of LGMD are still lacking, repeat electrocardiography (ECG)/Holter monitoring 
and echocardiography every 2 to 5 years are recommened, even for asymptomatic 
patients. Angiotensin-converting enzyme inhibitors and β-blockers, well described to 
have a beneficial effect on DMD, are recommended in the presence of left ventricular 
dysfunction 16.  
Since inflammation is an early and important pathophysiological event, the 
pharmacologic approach with steroids has been reported to be beneficial also in some 
types of LGMD, including LGMD2I, LGMD 2L and LGMD 2D, as already demonstrated 
for DMD 26-28. 
At present, there is no effective therapy to stop the lethal progression of these diseases, 
although several promising experimental strategies are currently under investigation. 
These include gene therapy aimed at reintroducing a functional recombinant version of 
the dystrophin gene using adeno-associated, lentiviral or adenoviral vectors, as well as 
modification of the dystrophin pre-mRNA, commonly referred as exon skipping. Both 
strategies held great promises with several clinical trials ongoing, but cell-based therapies 
and pharmacological approaches such as the up-regulation of utrophin or read-through 
strategies for nonsense mutations have also been investigated as summarized in figure 3. 
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Figure 3: The main stages in the pathological cascade arising from a null-mutation of the dystrophin 
gene, to the left, together with the potential therapeutic actions to combat each of these stages, to the 
right 29. 
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2.2 Gene therapy for DMD and LGMD 
 
The muscular dystrophies, including DMD and LGMD, caused by single gene mutation 
are attractive candidates for gene therapy.  
Since the discovery of the molecular basis of DMD in the 1980s, the introduction of a 
functional dystrophyn gene into the muscle cells has been deeply investigated, but 
numerous challenges delay the clinical implementation of this approach beyond initial 
expectations.  
DMD arises from null mutations in the dmd gene that result in the near complete absence 
of dystrophin protein, or in rare cases from mutations that lead to production of a non-
functional dystrophin, such as ones lacking critical domains near the carboxy-terminus of 
the protein. The allelic form, Becker muscular dystrophy (BMD), also arises from 
mutations in the dmd gene, however these mutations produce reduced amounts or 
truncated forms of dystrophin 30 
The size of the gene is a very big challenge since dystrophin is a 427 kDa cytoskeletal 
protein that is translated by the largest gene in the human genome (>2.4 MBP) with an 
mRNA of 14 kilobases (kb) (11 kb coding region of dystrophin from start codon to stop 
codon). Moreover, the muscular tissue makes up greater than 40% of the body mass, and 
a gene therapy approach for DMD requires the delivery of a new dystrophin gene to all 
muscles of the body, including the diaphragm and the heart. Since the disease requires the 
treatment of such a large mass of tissue, it is believed that the optimal strategy of delivery 
may be via the vasculature. Nevertheless, it is important to underlie that the therapeutic 
effect depends on the amount of protein delivered and the state of the disease at the time 
of treatment. In fact, in older patients, who show profound muscle lost as well as marked 
fibrotic changes and fatty deposition, dystrophin delivery to muscle cells might have a 
limited therapeutic efficacy 31. However, not all the systems for gene delivery are suitable 
for systemic use, due to different abilities to cross blood and tissue barriers together with 
immunogenic problems. 32. To overcome this problem, several groups are now 
investigating the potential of delivering utrophin, a dystrophin homologue, which is 
expected to be less immunogenic 33-34.  
The most promising viral vectors under investigation for gene therapy of DMD are adeno-
associated virus (AAV) given its known persistence in healthy muscle and absence of 
pathogenicity. However, its cloning capacity of ≤ 5 kb is a potentially limiting obstacle 
17 
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for successful DMD gene transfer. Therefore scientists paid attention to develop and 
characterize internally deleted, mini or micro-dystrophin constructs. Dystrophin is 
composed of 4 major structural domains: an N-terminal actin-binding domain; a central 
rod domain (a portion of which also binds actin) composed of 24 spectrin-like repeats and 
4 hinge domains (the fourth carries a WW domain important for binding to part of the 
DGC); a cysteine-rich domain; followed by a distal C-terminal domain that interacts with 
members of the DGC at the sarcolemmal level (Figure 4A) 35. The idea that functional 
mini dystrophin constructs may be useful came from the finding that BMD patients with 
very mild dystrophy can carry large deletions in the dmd gene 36. Consequently, mini-
dystrophin and highly miniaturized micro-dystrophin constructs are now being tested 
using both viral and non-viral models of delivery to determine their potential use as 
therapeutic proteins (Figure 4 B).  
A phase I gene therapy trial using AAV delivery of a mini-dystrophin gene supported the 
safety and tolerability of intramuscular delivery; however, dystrophin expression was 
limited 25,37. Since this first gene therapy trial in DMD, advances have been made in 
vectors design, muscle specific promoters, and mini-dystrophin constructs. 38. 
Others strategies of gene replacement are those that involve non-integrating gene delivery 
tools for a non viral gene therapy. Thus, one of the many advantages of this system over 
conventional viral vectors is to avoid any risk of immune response owing to viral capsids 
or other viral proteins and insertional mutagenesis 39. Among the non-integrating vectors, 
the most commonly used are plasmids, human artificial chromosomes (HACs) and 
transposons. Interestingly, almost all of them have a large cloning capacity, but there are 
still problems indeed plasmids are less efficient than the systemic injection of AAV 
vectors and can only be used for certain muscles 40. 
All the strategies mentioned above propose the replacement of the mutated gene with a 
new functional one; others promising approaches are related to the possibility to repair, 
instead of replace, the genetic defect in a mutation specific manner. 
Exon skipping for example is an alternative gene therapy approach for DMD, aimed at 
repairing the patient’s own gene, targeting the defect at the pre-mRNA level allowing one 
or more exons to be omitted to restore the dystrophin reading frame. This strategy is 
possible because approximately 70% of mutations responsible for DMD lead to a 
disrupted reading frame, resulting in a truncated non functional dystrophin protein 41-42. 
18 
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This result is obtained with different oligonucleotides, typically 20–30 nucleotides in 
length and complementary to regions of the pre-mRNA transcript. The antisense 
oligonucleotides (AON) target specific exons, hiding them from the splicing machinery 
and causing their skipping during the splicing process. Exon skipping is the only 
approach to show efficacy in a large animal (dog) model 43 and it has been considered the 
most promising strategy for DMD.  
Pre-clinical efficacy has been demonstrated in the mdx, dystrophin/utrophin knock-out 
mouse, and the dystrophin-deficient dog using two different AON, a 2’O-methyl-ribo-
oligonucleosidephosphorothioate (2’OMe) and a phosphorodiamidate morpholino (PMO) 
44-45. 
 
 
 
 
Figure 4: Micro-dystophin constructs 
(A) Dystrophin is crucial to link the cytosolic actin skeleton of the muscle fiber to the extracellular matrix. 
(B) Micro-dystrophin constructs that lack a large portion of the rod domain (ΔR4–R23), and the CT domain 
are currently being developed and tested to treat DMD. These micro-dystrophins are highly functional and 
are capable of restoring the DGC as shown. The only differences in the DGC that associates with micro-
dystrophin are a lack of nNOS binding and fewer associated syntrophins 31. 
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Also clinical trials have been performed with PMO and 2’OMe delivered directly to 
muscle and targeting exon 51 (Figure 5). Both oligomers demonstrated early evidence of 
efficacy 46-47, but their use was limited by the fact that they could not be used for a 
significant number of DMD patients, in particular those with large deletions or with 
mutations in regulatory or N-/C-terminal regions of dystrophin 42 were excluded. 
Gene targeting and endonucleases is another important tool for gene modification in 
muscular dystrophy and is based on the use of endonucleases engineered to induce 
double-strand breaks in specific DNA sequences that subsequently will be spontaneously 
repaired 48. 
Gene transfer in LGMD2D, is an approach that shows a more satisfactory outcome 
compared to DMD. First of all, the predominant mutation in LGMD2D is a missense 
mutation in the α-sarcoglycan gene, providing the basis for gene expression with lower 
immunogenicity compared to dystrophin. Moreover the full length α-SG cDNA is <2 kb 
and is well within the packaging capacity of AAV. In a double blind, randomized 
controlled study, was observed a persistent and sustainable gene expression of α-
sarcoglycan following gene transfer into extensor digitorum brevis muscle, mediated by 
AAV with a muscle-specific tMCK promoter, not previously used in a clinical trial 49. 
 
 
 
Figure 5: Mechanism of action of AO exon-skipping drugs.  
A) Dystrophin gene splicing in healthy muscle, in which all 79 exons are precisely spliced together to 
maintain the protein translational reading frame. B) A patient with DMD with a deletion of exon 50. The 
remaining exons are spliced together, but there is a disruption of the reading frame. C) The mechanism of 
action of PRO051, an AO drug targeting exon 51. The exon 51 sequence (adjacent to the missing exon 50 
sequence) is skipped, so that the mRNA splices exon 49 to 52. The new deletion is able to be translated into 
semifunctional Becker-like dystrophin, resulting in partial repair of the myofiber plasma membrane 50.  
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2.3 Cellular therapy for DMD and LGMD 
 
In the last years, cell therapies, in which cells bearing a functional dystrophin gene are 
transplanted to treat muscular dystrophy, acquired increased attention. Potentially 
therapeutic cells can be obtained either from patients, in which cells are corrected ex vivo 
and re-implanted (autologous transfer), or from healthy donors and injected into a 
dystrophic patient (allogeneic transfer). Ideally, transplanted cells should be able to 
migrate from blood to muscle and should form myotubes further they could also increase 
satellite cell into the niche and self-renew process to sustain a long-lasting treatment. 
Satellite cells are quiescent unipotent stem cells, located underneath the basal lamina of 
adult skeletal muscle fibers 51. In response to injury, satellite cells become activated and 
differentiate into myoblasts, which proliferate and fuse to repair or replace the damaged 
fibers. A fraction of activated satellite cells returns to quiescence to maintain the pool of 
progenitor cells. Given their natural commitment, it has been easy to consider satellite 
cells as the leading candidate for muscle regeneration in dystrophic mice, in fact, 
experiments carried out in the late 1980s by Partridge et al. showed that intramuscular 
injections of normal myoblasts into the mdx mouse resulted in cell fusion and expression 
of dystrophin in mdx myofibers 52. Unfortunately subsequent clinical trials failed to 
deliver significant levels of dystrophin, probably as a result of poor survival, limited 
migration and immune rejection of transplanted cells 53-54. 
In addition to satellite cells, several other stem cell types possess the ability to 
differentiate into myofibers. These include total bone marrow-derived stem cells, blood- 
and marrow derived side population and CD133+ cells, mesenchymal cells, and 
mesoangioblasts. In contrast to myoblasts and satellite cells, all of these have been shown 
to be compatible with systemic delivery through the circulatory system 31. 
Mesoangioblasts, for example, are vessel-associated stem/progenitor cells isolated from 
the skeletal muscle vasculature of different species and are able to differentiate into 
skeletal myofibres and to cross the vessel barrier, allowing them to be delivered through 
the bloodstream 55-56. Intra-arterial transplantation of these cells was able to ameliorate the 
dystrophic phenotype of different pre-clinical models (mice and dogs) of muscular 
dystrophy 56-58. Moreover mesoangioblasts modulated immune responses 59 and these 
results supported a phase I/II clinical trial based upon the intra-arterial allogeneic 
transplantation of these cells. 
21 
 
Introduction 
 
 
Also mesenchymal stem cells (MSCs) isolated from various sources have been shown to 
undergo some skeletal myogenesis 60-61, but work from independent groups demonstrated 
that, although they were able to engraft skeletal muscle, MSCs did not ameliorate the 
phenotype of mdx mice 62-63. 
In the last few years a growing interest about the therapeutic prospective offered by 
pluripotent stem cells is emerging. This involve the use of embryonic stem cells (ESC) 
and pluripotent stem cells (iPS). Both these cell types could be an extraordinary potential 
clinical tool useful for the treatment of any skeletal muscle degenerations 64. Recent work 
described the generation of myogenic progenitors from iPS cells that were able to play an 
active role during muscle regeneration in pre-clinical models for both DMD and 
LGMD2D 65-66. 
Deriving patient-specific iPS cells and expanding their differentiated progeny provides a 
unique tool for gene and cell therapies, even if further safety studies and improvements in 
protocols might be necessary to avoid any potential risk that could hamper the translation 
of these promising strategies into future clinical trials. 
 
 
2.4 Utrophin up-regulation 
 
Another promising pharmacological strategy for DMD is the up regulation of utrophin 
levels in muscle fibers. Utrophin is an orthologue of dystrophin and its expression can 
compensate for the absence of dystrophin, indeed utrophin shares many of the same 
binding proteins as dystrophyn.  
Some studies in mdx mice demonstrated that increasing utrophin levels in dystrophic 
muscle fibers could restore sarcolemmal expression of the dystrophin associated protein 
complex (DAPC) members and ameliorated the dystrophic phenotype 67-68.  
Utrophin expression is predominantly driven by two promoters: the promoter A and B 69. 
The former is responsible for the skeletal muscle-specific expression of utrophin, and the 
latter regulates its expression in endothelial cells 70. In particular, the knowledge of the 
utrophin-A promoter, started the research for small molecules that could stimulate the 
transcription of utrophin. 71. 
Utrophin-based drug therapy for DMD shows many advantages as it could be effective 
for all DMD patients, regardless of the specific gene defect and could be administered to 
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patients systemically because utrophin overexpression in tissues other than muscles does 
not seem to cause detrimental effect 72.  
High-throughput screenings allowed the identification of small molecules able to increase 
utrophin. These include the use of hergulin, which acts via the N-box motif of the 
utrophin A promoter, and L-arginine, which results in an increase in utrophin expression 
as a result of increased production of nNOS 71. 
Other approaches have been developed such as calpain inhibition 73 and overexpression of 
the small GTPase RhoA that account for an increase in utrophin expression with no 
change in transcription levels 74, but none of them is able to increase the protein level 
substantially and then achieve a complete recovery of the dystrophic phenotype in mdx 
mice.  
Also increased expression of integrins 75-76 and ADAM12 77 have been shown to 
upregulate utrophin expression and at the same time to improve the pathological 
phenotype.  
Furthermore, agents such as biglycan that stablize the DAPC also hold therapeutic 
promise, recruiting utrophin protein to the muscle membrane and so reducing muscle 
pathology in the mdx mouse model 78.  
Other approaches include the use of glucocorticoids to stabilize utrophin in muscle, due to 
their ability to enhance the activity of an internal ribosome entry site located within the 
utrophin A 5′UTR 79 and custom-designed proteins with zinc finger motifs that have been 
shown to act as strong transcriptional activators of the utrophin A promoter 80.  
Finally Ervasti and colleagues developed a direct protein-replacement therapy for the 
treatment of skeletal and cardiac muscle diseases caused by loss of dystrophin, delivering 
utrophin protein directly 81. 
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2.5 Read-through strategies for suppression of nonsense mutations 
 
Read-through strategy is a molecular approach based on treatment of patients carrying a 
non sense mutation with chemicals that induce read through of premature stop codons and 
this is suitable for approximately 10-15 % of DMD patients 82. Small molecules that are 
able to introduce a conformational change in the mRNA structure can be administred, 
allowing the ribosomal subunit to substitute a mutation-induced stop codon with a single 
amino acid thus resulting in an increase read-through of the premature stop codon and 
production of a full length protein 83. 
Pre-clinical studies, in the mdx mice model, demonstrated that a treatment with the 
aminoglycoside Gentamicin, could suppress stop codons not only in vitro but also in vivo 
enhancing dystrophin expression 84. These results led to clinical trials in DMD patients 
with stop codons, treated weekly or twice weekly for six months using gentamicin. In a 
most recent study, 3 out of 12 DMD patients treated with gentamicin for 6 months 
revealed 13 to 15% of normal dystrophin levels, associated with reduced serum CK, 
stabilization of strength and a slight increase in forced vital capacity 85. However, the 
remaining patients revealed no or only moderate dystrophin expression.  
Another agent for stop codon mutation is the orally bioavailable drug called Ataluren 
(also known as PTC124). Pre-clinical studies in mdx mice showed dystrophin restoration 
up to ~20% of normal levels and an improved contractile properties of treated skeletal 
muscles for a limited period of time 86. Unfortunately, no convincing evidence has been 
presented regarding the increase of dystrophin expression in cardiac muscle after ataluren 
treatment.  
A phase I study in healthy volunteers established the safety of Ataluren in humans 87 and 
led to a phase IIa proof-of-concept study in DMD/BMD patients and subsequently to a 
randomized, double-blind, placebo-controlled dose-ranging phase IIb clinical trial. 
Although a good safety profile emerged from these studies, the preliminary results 
demonstrated no significant difference in functional tests 83. 
Further, it has been demonstrated that Ataluren was also able to induce read-through of a 
stop codon in cells derived from a LGMD2B patient with a R1905X mutation in the gene 
for dysferlin and to produce enough amount of protein to rescue myotube membrane 
blebbing 88. 
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Chapter 3: Nitric Oxide and Muscular dystrophies 
 
3.1 Nitric Oxide and nitric oxide synthases 
 
Nitric Oxide (NO) is a gaseous messenger, synthesized from L-arginine and oxygen by 
NO synthases (NOS) in almost all mammalian cells and tissues to regulate key 
physiological events of adult organisms 89-90. Three distinct isoforms of NOS have been 
identified, two of which, namely the endothelial (eNOS) and neuronal (nNOS) isoforms, 
are regulated by second messengers, whereas the inducible one by cytokines and bacterial 
products (iNOS). All three NOS isoforms are expressed in skeletal muscle, but differ in 
their mechanisms of activation, regulation and catalytic activity. Neuronal NOS is 
abundant at the surface of type II fibers (fast twitch), whereas it is less represented in type 
I (slow twitch) fibers 91.  
Neuronal and endothelial NOS are constitutively expressed and require the 
Ca2+/calmodulin complex for their activation. Changes in the expression of these enzymes 
may occur in skeletal muscle, in fact expression of nNOS is increased by crush injury, 
muscle activity and ageing 92; also changes in eNOS expression are described after 
exercise and shear stress 93. These changes, however, are usually of small extent. Both 
nNOS and eNOS produce NO at low, physiological levels (in the pico to nanomolar 
range) for short periods. Conversely, iNOS is expressed in skeletal muscle primarily 
under severe inflammatory conditions, such as in the course of autoimmune inflammatory 
myopathies 94 and after crash injury. The activity of iNOS is independent of the 
Ca2+/calmodulin complex and generates NO at high concentrations (micromolar range) 
for prolonged periods. 
In the recent years, many studies have uncovered an increasingly important role of 
physical association of the NOS isoforms with several regulatory and structural proteins 
95. Interestingly, these protein–protein interactions, as well as regulating the activity of 
NOSs often target them to cellular membranes. The N-terminus of nNOS contains a PDZ 
(post-synaptic density protein-95, discs-large, Z0-1) domain that allows interactions of 
the enzyme with other PDZ containing proteins at the cellular plasma membrane. In 
skeletal muscle, the localization of nNOS to the dystrophin–glycoprotein complex at 
sarcolemma, due to the binding via one of these PDZ-containing proteins, α1-syntrophin 
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96, is a key aspect that explains the coupling of NO generation with muscle contractile 
activity. 
Pathological features of muscular dystrophies are, at least in part, due to the displacement 
of nNOS from the sarcolemma as a consequence of the disruption of the dystrophin–
glycoprotein complex. 
 
 
3.2 Nitric Oxide and the Therapy of Muscular Dystrophies 
 
Whereas the genetic (exon skipping and antisense oligonucleotides) and stem cell 
approaches appear to be significant steps forward to a resolutive therapy for muscular 
dystrophies, they are expensive and still not really available for all patients as the results 
of the last clinical trials indicate (Pichavant, Aartsma-Rus et al. 2011; Cirak, Feng et al. 
2012). Moreover, they are direct to specific subsets of population (e.g. about 13 % in the 
case of exon 51 skipping) and cannot restore fully the damage already caused by the 
disease to the muscle. 
In this context, the need for novel therapeutic strategies that can limit muscle wasting and 
ameliorate the dystrophic symptoms is particularly urgent also considering the adverse 
side effects of the current therapy with corticosteroids. Therefore, classical 
pharmacological approaches appear therefore still attractive and of significant value, as 
they address all patients and at affordable costs 97.  
Nitric oxide is known to exert many important functions in skeletal muscle physiology: 
for example it regulates the muscle force excitation–contraction coupling together with 
myogenesis and muscle repair, thus suggesting a possible use of NO as a tool for 
therapeutic strategies in Duchenne, Becker and limb-girdle muscular dystrophies, where 
genetic alterations in genes coding for structural muscle proteins lead to repeated and 
enhanced muscle damage during physiological activity. 
The role of NO in therapy is also supported by the demonstration of a rescue in mdx and 
dystrophin/utrophin double-knockout mice by over-expressiong the nNOS transgene. Of 
interest, the transgenic nNOS acts without a strict localisation to the sarcolemma, 
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indicating that generation of NO per se was sufficient to exert the beneficial effect 98-99. 
The efficacy of therapies based on the administration of NO has, thus, been investigated 
by several groups in mouse models of muscular dystrophy.  
Approaches with only NO donors or the NOS substrate L-arginine yield some 
amelioration of the mdx mouse dystrophic phenotype; nevertheless, none of these studies 
report long-term observations. Thus, the assessment of the validity of NO 
donation/generation as a therapeutic strategy inducing persistent beneficial effects could 
not be defined 100-101. 
The NO-based approaches that have been tested so far include:  
 
(i) administration of the NO precursor aminoacid  L-arginine, alone or in 
combination with corticosteroids;  
(ii) NO donation per se; 
(iii) NO donation combined with glucocorticoids; 
(iv) NO donation combined with non steroidal anti-inflammatory activity; 
(v) Administration of 5′ phosphodiesterases inhibitors (Tadalafil and Sildenafil) 
that inhibit hydrolysis of cGMP by phosphodiesterases prolonged NO effects. 
 
NO donation per se has been tested using the organic nitrate isosorbide dinitrate and 
molsidomine.  
Isosorbide dinitrate alone is not really effective, and molsidomine shows a moderate long 
term efficacy 1, but the reason why molsidomine is more effective than the other NO 
donors tested so far remains to be established. A possible explanation could be found in 
recent studies in which  molsidomine has been demonstrated to be particularly effective in 
increasing satellite cells number and preventing the adipogenic differentiation of 
mesenchymal fibro-adipogenic progenitors (FAPs) residing in the muscle, thus reducing 
fibrosis. In particular, the inhibition of adipogenesis is due to NO-induced increased 
expression of miR-27b leading to down-regulation of peroxisome proliferator-activated 
receptors gamma (Pparγ1) expression in a pathway independent of cGMP generation 102. 
It has also been shown that molsidomine treatment modulates effectively the 
characteristics of the inflammatory infiltrate within dystrophic muscles, enhancing its 
healing functions 103. Distinct effects depend on the phase of the disease. Initially, the 
treatment with molsidomine contributes to a more efficient macrophage recruitment 
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inside the dystrophic muscle, in order to promote a more efficient clearance of cell debris 
and an effective tissue regeneration. Later molsidomine decreases the extent of the 
inflammatory infiltrate, whose persistence worsens muscle damage 103. Molsidomine 
efficacy could also depend on the pharmacokinetic profile of NO release by the drug, or 
on the release of biologically active nitrites and nitrates 104, which have beneficial 
functions in skeletal muscle and have been shown to ameliorate the dystrophic phenotype 
105-107. Despite the positive results obtained with molsidomine, a strategy based on NO 
donation alone appears not endowed with the characteristics of clinical efficacy, needed 
for an effective pharmacological therapy. 
An alternative strategy is to use NO donation in combination with anti-inflammatory 
drugs. For example, a study in mdx mice reports that the association of the corticosteroid 
deflazacort with L-arginine spares mdx dystrophic limb muscle from exercise-induced 
damage and induces a persistent functional improvement in distance run 108. This 
approach, even substantial, still implies the use of corticosteroids. 
In order to avoid corticosteroids, different strategies have been tested, in which the anti-
inflammatory activity is obtained using non-steroidal anti-inflammatory agents 
(NSAIDs). Two approaches have been proposed: the combination of two different 
molecules isosorbide dinitrate and ibuprofen administrated together and a strategy in 
which a the two activities are combined together in a single molecular entity consisted of 
compounds of the CINOD class (cyclooxygenase-inhibiting nitric oxide (NO) donators) 
109.  
Using these drugs or the combination important therapeutic effects in both the α-
sarcoglycan null and the mdx mouse models have been observed in the absence of 
relevant side effects or signs of toxicity. Of interest, the beneficial effects are persistent 
(up to 12 months, that is the observation period set to mimic a chronic treatment) and both 
approaches are able to slow down the dystrophic progression, maintaining the functional 
capacity of muscles. At biochemical level several mechanisms synergize to obtain the 
therapeutic effect of the combined therapy: 
• reduced fibers damage and inflammation,  
• significant increase in the number and differentiation capacity of myogenic 
precursor cells, which preserve the long-term regeneration capacity of muscle 110-
111 (Figure 6).  
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• effects on blood flow. NO has vasodilating and angiogenic properties; the former 
contributes  to reduce muscle ischemia induced by nNOS displacement and 
increase glucose uptake and energy generation and the latter can contribute in 
muscle repair 112-113. 
An additional interesting aspect of these therapies is that they significantlyenhance  the 
homing of exogenously added myogenic stem cells to dystrophic muscles 110-111, 
suggesting the possibility of obtaining synergic effects by combining pharmacological 
and cell therapy approaches. 
 
 
Figure 6:  Nitric oxide and muscle repair: Multiple actions converging on therapeutic efficacy.  
Schematic diagram summarizing the different actions through which NO, endogenously generated by iNOS 
or nNOS, or administered through NO donors stimulates muscle repair, alone or in combination with 
NSAID. NO stimulates satellite cells activation, myoblasts differentiation and fusion to form new fibres. 
Both NSAIDs, and to a lesser extent NO, modulate the nature of the inflammatory infiltrates 
(mainlymacrophages) 114. 
 
 
In spite of no significant differences in terms of efficacy between CINOD and the 
combination of NO-donating drugs plus NSAID have been observed, an advantage in 
therapeutic perspective of the use of a combination of drugs is the possibility of titrating 
the two active principles independently, thus optimizing their use of single patients 97.  
The therapeutic potential of the combination o have also been tested on dystrophic 
patients in an open-label pilot study in a cohort of adult patients affected by Duchenne, 
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Becker and limb-girdle muscular dystrophies. The trial have been designed mainly to 
evaluate safety and tolerability of the drug combination, but exploratory measures of 
efficacy, such as the motor function measure scale, have also been applied. The 
combination shows good safety and long-term tolerability profiles with only few and 
transient side effects. Of importance, the exploratory efficacy measures point out a trend 
towards amelioration, in particular better performance in the Motor Function Measure 
scale 115. These results strongly indicate that the systemic administration of a combination 
of NO-donating drugs and NSAIDs (and possibly of CINODs) is of potential clinical 
relevance and should be optimised and further investigated in future clinical studies. 
Moreover, the combination of NO donation and anti-inflammatory activity ameliorates 
cardiac dysfunction in mdx mice, an event that characterizes advanced disease 116. This 
effect is shared by sildenafil, which shows significant cardio protective actions 117. 
Whether sildenafil has beneficial effect also on skeletal muscle needs to be clarified, even 
if some initial promising results have been reported 118. However,  many of the action of 
NO on muscle myogenesis and repair are independent of cGMP generation, including the 
effects of NO on the proliferation and differentiation of stem cells, on the control of 
inflammation and on the regulation of gene transcription and regulatory miRNA activity 
103,119-121 distinguishing between NO-donating drugs and sildenafil. 
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Chapter 4: Mitochondria and Mitochondrial Dysfunctions in Muscular 
Dystrophies 
 
4.1 Mitochondria: Structure and function 
 
Mitochondria are membrane bound organelles involved in many important biological 
functions, for instance they are the major sites of oxidative energy production in 
eukaryotic cells. They in fact produce adenine triphosphate (ATP) as the main source of 
cellular energy through a process called oxidative phosphorilation (OXPHOS) 122-123. 
According to the endosymbiont hypothesis, mitochondria arose from the engulfment of 
aerobic eubacteria by a primordial anaerobic eukaryote.124. Thus, the organelle has its 
own genetic system that exhibits several prokaryotic features including a compact circular 
DNA (mtDNA), multigenic RNA transcripts and bacteria-like antibiotic sensitivity of the 
translational apparatus. mtDNA encodes only 13 proteins and the 22 tRNAs and 2 rRNAs 
required for their translation within the mitochondrial matrix 125-126. 
Mitochondria play essential and diverse roles in the physiology of eukaryotic cells, not 
only providing energy, but they also participate in numerous metabolic reactions and play 
central roles in apoptosis 127. Impairments of mitochondrial functions have been 
implicated in several human pathologies, among which age-related diseases, cancer and 
neuromuscular diseases. 
In the 1950s, electron microscopy studies led to the canonical view of mitochondria as 
bean-shaped organelles consisting in two double lipid membranes: the outer membrane 
that covers the organelle and the inner membrane that folds over many times arising 
structures termed cristae. The space between the outer and inner membrane of the 
mitochondria is called the intermembrane space and the volume enclosed by the inner 
membrane is called matrix that contains a highly-concentrated mixture of hundreds of 
enzymes. Electrons from oxidative substrates are transferred to oxygen, through a series 
of redox reactions, to generate water. In the process, protons are pumped from the matrix 
across the mitochondrial inner membrane by respiratory complexes I, II III, and IV. When 
protons return to the mitochondrial matrix following their electrochemical gradient, ATP 
is synthesized via complex V (ATP synthase) 128. 
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In the last years taking advantage from fluorescence microscopy techniques has been 
demonstrated that the mitochondrial structure is highly dynamic 129. In mammalian cells 
mitochondria morphology depends on cell type and, even in the same cell, mitochondria 
can change morphologies, ranging from small spheres or short rods to long interconnected 
tubules 130. To this end, they continuously and reversibly rearrange their structure through 
the tightly-regulated processes of fission and fusion. In particular, mitochondrial fusion is 
regulated by the activity of three large GTPase proteins, called mitofusin-1 and 2, and 
optic atrophy-1 (Opa1), whereas the fission process is mainly regulated by the GTPase 
dynamin-related protein-1 (Drp1) 131. 
Mitochondria are also defined as dynamic organelles because they are actively 
transported in cells determining specific subcellular distributions. Depending on the 
cellular context, these transport processes can ensure proper inheritance of mitochondria 
or can recruit mitochondria to active regions of the cell. For example, in budding yeast, 
mitochondria are transported into and retained in the developing bud to ensure 
mitochondrial inheritance to the daughter cell 132. 
Finally, the plasticity of mitochondria involves the internal structure of the organelle that 
can change in response to their physiological state. Purified mitochondria placed in low 
ADP conditions have limited respiration and have an ‘orthodox’ morphology, 
characterized by narrow cristae and few cristae junctions per cristae compartment. Under 
high ADP and substrate conditions, isolated mitochondria have high respiratory activity 
and a ‘condensed’ morphology, characterized by larger cristae and several cristae 
junctions per cristae compartment 133 (Figure 7). 
It is known that the gaseous messenger NO play a crucial role in the regulation of 
mitochondrial function competing with oxygen and inhibiting complex IV. NO at 
physiological nanomolar concentrations reversibly binds the cytochrome c oxidase 
blocking the activity of the enzyme 134-136 and thus negatively regulating mitochondrial 
oxidative phosphorylation. Recently it is has been demonstrated that NO is also able to 
inhibit fission during myogenic differentiation allowing myogenic process to occur 137.  
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Figure 7: Mitochondria as dynamic organelles: A) Mitochondrial fusion and fission control 
mitochondrial number and size. B) In mammalian systems, mitochondria are distributed throughout the 
cytoplasm by active transport along microtubules and actin filaments. Distinct molecular motors transport 
the mitochondria in anterograde or retrograde directions. C) Inner membrane dynamics. The diagram 
indicates the different regions of the inner membrane. The bottom panels show electron microscopy (EM) 
tomograms of two mitochondria under different metabolic conditions (red, outer membrane; yellow, inner 
boundary membrane; green, cristae membrane). 
 
 
4.2 Mitochondrial biogenesis 
 
The renewal of mitochondria through the process of biogenesis is essential to maintain 
mitochondrial integrity and changes in mitochondrial mass have been documented in both 
normal and disease states. For instance, mitochondria differentiate post-natally to acquire 
increased respiratory capacity as an adaptation to oxygen exposure outside of the womb 
138. Moreover mitochondrial biogenesis increases in muscle cells upon exercise 139 or in 
response to contraction induced by chronic electrical stimulation 140. Also thyroid 
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hormones have long been associated with increased mitochondrial mass and the elevated 
expression of PGC-1α gene 141 and finally, developmental signals induce the proliferation 
of mitochondria as occurs in the brown fat of rodents and other mammals during adaptive 
thermogenesis 142-143.  
PGC-1α is currently considered to be the most important regulator of mitochondrial 
biogenesis 144. The ability of PGC-1α to regulate mitochondrial mass is due to its capacity 
to co-activate multiple transcription factors involved specifically in the regulation of 
nuclear genes encoding mitochondrial proteins 145-146. In particular, PGC-1α interacts with 
NRF-1 and 2 to transactivate genes of the respiratory chain, of mitochondrial import 
machinery and transcription factors of mtDNA, such as Tfam, TFB1M and TFB2M 147-148 
149. 
More recently, the estrogen-related receptor alpha (ERRα) has also been implicated as an 
important regulator of oxidative metabolism. Evidence suggests a correlation between 
ERRα and PGC-1α, in particular PGC-1α regulates ERRα activity , but inhibition of 
ERRα in cells decreases the ability of PGC-1α to induce mitochondrial biogenesis and 
cellular respiration 149-151. The ability of PGC-1α to integrate the transcriptional activity of 
these and other several nuclear transcription factors provides the mechanism by which the 
coactivator can coordinate the large number of genes required for mitochondrial 
biogenesis.  
PGC-1α levels depend on the oxidative capacity of the tissue, for instance it is highly 
expressed in oxidative tissues such as brown fat, heart and skeletal muscle.  
PGC-1α is dynamically regulated at the level of mRNA and protein expression in 
response to a variety of signaling pathways involved in cellular growth, differentiation, 
and energy metabolism. Moreover, PGC-1α expression is induced by multiple stimuli 
involved in the regulation of mitochondrial biogenesis, such as chronic exercise or thyroid 
hormone treatment 141,152-153.  
In skeletal muscle, the increase of Ca2+ concentration and calcium/calmodulin-dependent 
protein kinase IV (CaMKIV) activation, stimulate binding of CREB protein to the CRE 
region in the PGC-1α promoter.  
It has also been shown that PGC-1α is involved in an autoregulatory loop controlling its 
own transcription, in fact, PGC-1α coactivates myocyte enhancer factor (MEF)-2, that in 
turn binds to the PGC-1α promoter regulating the expression of the coactivator 154 itself.  
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PGC-1α is also regulated at post-translational level (Figure 8). In fact, it is directly 
activated by a Sirt1-dependend deacetylation and by specific phosphorilations at 
threonine-177 and serine-538 by AMP-activated kinase (AMPK) in response to changes 
in nutrient or energy depletion 155-156. 
 
 
 
Figure 8:  Post-traslational control of PGC-1α 
PGC-1α is activated via post-transcriptional phosphorylation by AMPK or by deacetylation via SIRT1 in 
response to nutrient deprivation. Induction or activation of the coactivator can enhance mitochondrial 
biogenesis and oxidative function through the coactivation of multiple transcription factors involved in 
respiratory gene expression 157 
 
 
The importance of PGC-1α in regulating mitochondrial content in skeletal muscle has 
been demonstrated with the use of animal and cell culture models in which the expression 
of the coactivator has been markedly altered 158-159. More specifically, over-expression of 
PGC-1α has been shown to increase the expression of nuclear encoded mitochondrial 
proteins involved in the expansion of the mitochondrial reticulum 160. Ectopic expression 
of PGC-1α in C2C12 myoblasts increases nuclear (cytochrome c, COX subunit IV) and 
mitochondrially (COX subunit II) encoded electron transport chain (ETC) mRNAs and 
amplifies mtDNA copy number 149.  
The induction of mitochondrial biogenesis has been further studied with the use of PGC-
1α transgenic mice. Gain-of function experiments establish that overexpression of the 
coactivator in vivo activates mitochondrial proliferation; furthermore, muscle-specific 
overexpression of PGC-1α enhances the expression of mitochondrial genes involved in 
the oxidative phosphorylation. In addition to the effects of PGC-1α on the steady-state of 
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mitochondrial mass in skeletal muscle, the transcriptional coactivator is also highly 
implicated in induced-organelle biogenesis for instance during endurance exercise 161-162.  
Exercise enhances the PGC-1α-dependent mitochondrial biogenesis, whereas chronic 
muscle disuse results in a decrease of mitochondrial mass, along with concomitant 
reduction of PGC-1α level 163. Similarly, the process of aging is associated with 
concomitant reduction of mitochondrial content, endurance performance and PGC-1α 
protein expression 164. Although the full role of PGC-1α in aged-related deficits of 
mitochondrial content remains to be determined, some of the pathways involved in the 
transcriptional activation of PGC-1α are impaired with age. The importance of PGC-1α in 
maintaining basal mitochondrial content, as well as its potential involvement in 
physiological and pathological processes highlights the interesting of understanding in 
detail how its expression and activity are controlled. 
 
 
4.3 Nitric Oxide Regulation of Mitochondrial Biogenesis 
 
The hypothesis of an involvement of NO in the regulation of mitochondrial biogenesis 
came from observations by several groups about the role of NO, either exogenous or 
generated by eNOS, in the differentiation programme of the brown adipose tissue 
(BAT)165-166. It was found that treatment with NO-releasing drugs increases the mtDNA 
content167. The NO-dependent mitochondrial biogenesis occurs through activation of 
PGC-1α, NRF-1 and the mitochondrial transcription factor A (Tfam). Using a cyclic 
GMP (cGMP) analogue and a guanylate cyclase inhibitor, it has been demonstrated that 
mitochondrial biogenesis depends on this second messangers. Activation of guanylate 
cyclase and generation of cGMP are known to take place at physiological concentrations 
of NO indicating that mitochondrial biogenesis is a physiological process regulated by 
NO. In animals acclimatized to cold high levels of noradrenaline (NA) are released from 
sympathetic nerve terminals stimulating brown adipocytes,  with an increase of eNOS 
expression, NO and cGMP production in both cytosol and nucleus and resulting in 
enhanced expression of uncoupling protein 1 (UCP1). UCP1 is an inner mitochondrial 
membrane proton channel that dissipates the inner trans-membrane potential to produce 
heat 168-169. Interestingly, NA also induces expression of PGC-1α, which binds UCP1 
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promoter and increases UCP1 expression 170. Interestingly, such function by NO is 
associated with PKG-mediated brown fat cell differentiation suggesting a key role of NO 
and cGMP in BAT differentiation 171. Thus, NO and/or cGMP levels in brown adipocytes 
are linked to cell activation, mitochondrial biogenesis and heat production. 
Experiments in mouse white-fat 3T3-L1, human U937 monocytic and HeLa epithelial 
cells, as well as rat L6 myoblasts and PC12 neurosecretory cells, show similar results to 
those obtained in brown adipocytes, revealing that the NO-dependent mitochondrial 
biogenesis is restricted neither to brown adipocytes and their differentiation processes nor 
to a specific cell lineage or species 167,172. An important aspect of NO-dependent 
mitochondrial biogenesis is that it leads to formation of functionally active mitochondria. 
In particular, the newly generated mitochondria are capable of sustaining coupled 
respiration, and generate ATP, through the oxidative phosphorylation pathway. 
Interestingly, this increase in ATP generation by mitochondria is not accompanied by a 
decreased generation of ATP through the glycolytic pathway, yielding a steady state 
concentrations of ATP more higher than those observed in cells not exposed to NO.  
The obligatory role of eNOS in mitochondrial biogenesis was further investigated by 
using eNOS-/- mice. Histological analysis indicated that BAT of eNOS-/- is functionally 
inactive, and indeed exposure of these animals to cold did not result in the 
mitochondriogenetic process that is commonly observed in wild-type animals 167. In 
addition, deletion of eNOS was sufficient to reduce the mitochondrial mass even in 
tissues that have a basal expression of nNOS, and possibly iNOS, such as the brain, liver, 
muscle and heart. The reduced mitochondrial content in tissues from eNOS-/- mice was 
accompanied by reduction of both basal oxygen consumption and steady state levels of 
ATP associated with a significant reduction in the mitochondrial size. This occurred in 
tissues dependent on oxidative metabolism, such as the brain, and in glycolytic tissues, 
such as the gastrocnemius muscle, suggesting that the effect of NO on mitochondrial 
biogenesis is a general phenomenon. Interestingly, in the gastrocnemius muscle 
mitochondrial biogenesis is important for the conversion of type II (glycolytic) fibers into 
type I (oxidative) fibers 173. The mitochondrial volume and network extension 174 have 
been shown to correlate positively with the efficiency of the mitochondrial respiratory 
function. Thus, it is likely that the decrease in mitochondrial size observed in tissues from 
eNOS-/- mice is a morphological feature that correlates with reduced mitochondrial 
function. 
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The importance of NO as a mitochondrial biogenetic stimulus has also broad implications 
in term of pathology. Impairment of mitochondrial function is associated with 
neurodegenerative diseases, neuromuscular disorders, liver and heart failure, and type 2 
diabetes 159,175-178. The possibility of generating new, metabolically active mitochondria 
might therefore improve the outcome of these pathologies. 
 
 
4.4 Mitochondrial dysfunction in muscular dystrophies 
 
Mitochondrial dysfunctions can be defined as alterations in the mitochondria, including 
mitochondrial uncoupling, mitochondrial depolarization, inhibition of the mitochondrial 
respiratory chain, mitochondrial network fragmentation, mitochondrial DNA depletion, 
mitochondrial or nuclear DNA mutations and the mitochondrial accumulation of protein 
aggregates.  
All these dysfunctions are known to alter the ATP production and are observed in several 
pathological states or diseases, including cancer, obesity, muscle and neurological 
disorders.  
Mitochondrial dysfunction has long been suspected to be an important pathogenetic 
feature also in muscular dystrophies even if their role in this kind of pathologies is not 
fully understood. Alterations of mitochondrial function have been described so far in the 
pathogenesis of several muscular dystrophies such as congenital muscular dystrophy 
(CMD), limb-girdle muscular dystrophy type 2 (calpainopathy) and Duchenne muscular 
dystrophy. 
 
1. Mitochondrial dysfunction due to dysregulation of mitochondrial permeability 
transition pore (mtPTP) 
The most described mitochondrial dysfunction in the biology of muscular dystrophy is 
exemplified in Collagen VI myopathies that share a dysregulation of an inner membrane 
high-conductance channel, the mitochondrial PTP 179-180.  
In particular, Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy 
(BM) are muscle diseases due to mutations in the genes encoding the extracellular matrix 
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protein collagen VI and key events in their pathogenesis are dysregulation of the 
mitochondrial permeability transition pore and inadequate removal of defective 
mitochondria, which amplifies the damage.  
Myoblasts obtained from patients with UCMD and BM exhibit a latent mitochondrial 
dysfunction, irrespective of the genetic lesion responsible for the lack or deficiency of 
collagen VI. In UCMD myoblasts, the threshold for PTP opening is very close to the 
resting membrane potential, hence a depolarization can trigger pore opening and ATP 
depletion. Collectively, myoblasts obtained from patients with UCMD display functional 
and ultrastructural mitochondrial alterations and increased apoptosis due to inappropriate 
opening of the mtPTP. These alterations can be normalized by treatment with cyclosporin 
A (CsA), a widely used immunosuppressant that desensitizes the permeability transition 
pore independently of calcineurin inhibition. 
CsA is used in mouse models and also in clinical trials for patients affected by UCDM 
and BM demonstrated that collagen VI myopathies can be effectively treated with drugs 
acting on the pathogenic mechanism downstream of the genetic lesion, and they represent 
an important proof of principle for the potential therapy of genetic disease 181-182. 
Interestingly, a mtPTP dysregulation is also observed in vitro in myoblasts obtained from 
muscle biopsies of patients with limb-girdle muscular dystrophy (LGMD) type 2B, but 
not in myoblasts from patients with BM, merosin-deficient CMD, LGMD2A or Duchenne 
muscular dystrophy (DMD) 183. 
 
 
2. Mitochondrial dysfunction in DMD and LGMD 
 
Abnormalities in mitochondrial function have been also implicated in the pathogenesis of 
DMD and LGMD.  
Biochemical and ultrastructural abnormalities have long been recognized in DMD 
patients and carriers. Electron microscopic analyses performed on muscle biopsies from 
obligatory carriers of DMD show massive aggregates of subsarcolemmal mitochondria, 
some with paracrystalline inclusions 184. In young DMD patients an increased fragility of 
the mitochondrial membranes is observed, indicating that mitochondria could be involved 
early in the disease process185. Furthermore, more recently, it has been documented a 
general metabolic crisis in dystrophic muscle of Duchenne and Limb girdle 2D patients 
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with severe downregulation of nuclear-encoded mitochondrial genes 186. DMD patients 
also exhibit a reduced transcription of the genes involved in energy metabolism as 
demonstrated by genome-wide gene expression profiling of skeletal muscle 187. 
In animal studies, mdx mice, compared with normal mice, exhibit abnormalities in 
mitochondrial respiratory function, greater ROS buffering capabilities, and susceptibility 
to Ca2+ inducing opening of the mt PTP complex 188. Gene transfer and overexpression of 
PGC-1α in post necrotic dystrophin-deficient muscles restores mitochondrial function and 
exerts a moderating effect regarding the activation of proteolytic and apoptotic signaling 
associated with disease progression. 
The mitochondrial abnormalities in DMD-associated heart failure support a critical role 
for dystrophin in maintaining optimal coupling between metabolism and contractile 
function. Mitochondrial abnormalities, which include changes in energy substrate 
utilization and cell death signaling due to increased permeability of mitochondrial 
membranes, disruption of Ca2+ homeostasis, and ROS production, could be responsible 
for the clinical manifestations of overt cardiomyopathy. It has been suggested that 
mitochondrial changes in the dystrophin-deficient heart may  provide the rationale for 
mitochondria targeted therapies 189. 
The extent of mitochondrial abnormalities across the genetic spectrum of autosomal 
recessive LGMD is currently unclear but it is an interesting field of study. There are 
isolated case reports of LGMD, that show some mitochondrial morphologic 
abnormalities, including ragged-red fibers (a histochemical hallmark of abnormal 
mitochondria in skeletal muscle fibers), decreased COX histochemical staining, and  
ultrastructural aberrations observed by electron microscopy 190. For instance, ragged-red 
fibers have been reported in instances of dysferlinopathy 191. 
 
 
3. Mitochondrial dysfunction associated with Calpain3 (CAPN3) gene and other 
muscular dystophies 
 
Mutations in the non-lysosomal cysteine protease calpain-3 (CAPN3) gene cause a 
recessive form of limb girdle muscular dystrophy type 2A (LGMD2A). 
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Ultrastructural and biochemical mitochondrial abnormalities have been reported in 
skeletal muscles of calpain-3 knockout (C3KO) mouse associated with reduced oxidative 
ATP production 192. 
These data suggest that mitochondrial abnormalities leading to oxidative stress and 
energy deficit are important pathological features of calpainopathy and might represent 
secondary effects of the absence of CAPN3. 
Patients with facioscapulohumeral muscular dystrophy (FSH-MD) display derangements 
in the oxidative stress responses and reduced levels of systemic antioxidative molecules 
(low levels of zinc, selenium, and vitamin C). Systemic oxidative stress and 
mitochondrial dysfunction in patients with FSH-MD correlate with abnormalities in 
skeletal muscle functional parameters, providing the rationale for therapeutic use of 
antioxidants in maintaining FSH-MD muscle functions 193.  
Abnormalities in mitochondrial proteins and the ubiquitin-proteasome system are 
potentially relevant also in DM2 (Myotonic Dystophy type 2) pathogenesis. 
Mitochondrial proteins, including elongation factor-Tu, heat shock protein 60, glucose-
regulated protein 75, and dienoyl CoA isomerase, an enzyme involved in fatty acid 
degradation 194 are downregulated in DM2 myotubes.  
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Muscular dystrophies are heterogeneous genetic diseases affecting skeletal muscle. At 
present there is no satisfactory therapy for muscular dystrophies, apart for the treatment 
with corticosteroids that, however, provides only temporary improvements and is 
associated with severe side effects. To this end elucidation of novel possible targets is 
necessary to develop new therapeutic strategies and is the goal of this project. 
Since mitochondria are emerging as determinant in many muscle disorders including 
muscular dystrophy, the first aim of this study is the investigation of the role of 
mitochondria in the pathogenesis of Limb Girdle muscular dystrophy 2D , studying a-
sarcoglican-null mice. 
Moreover, during the years, nitric oxide donors have been identified as good candidate 
molecules for Duchenne Muscular dystrophy therapy and our group has recently 
demonstrated that the NO donor molsidomine is able to slow disease progression and to 
restore the functional capacity of damaged muscles, significantly enhancing spontaneous 
and forced motor activities. 
In this context, the second aim of the study is the evaluation of the impact of molsidomine 
treatment on mitochondrial function of dystrophic mice. 
All the experiments were carried out comparing wild-type mice to a-sarcoglican-null mice 
treated with standard diet or with diet containing the NO-donor molsidomine. 
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MATERIALS AND METHODS 
 
Animals 
α-Sarcoglycan (α-SG) null mice C57BL/6J were a kind gift of K. Campbell (Iowa 
University, Iowa City, IA, USA) and C57BL/6 WT mice (C57Bl10SnJ strain) were 
purchased from Charles River (Wilmington, MA, USA) and treated in accordance with 
the European Community guidelines and with the approval of the Institutional Ethical 
Committee. Animals were used when 5 months old, since from 4 months of age αSG-null 
mice are characterized by the development of histopathological features of muscle 
dystrophy with ongoing fibre degeneration and modest spontaneous regeneration 20. 
The mice were housed in an environmentally controlled room (23°C, 12h light–dark 
cycle) and provided food and water ad libitum. Standard diet (STD) or a diet containing 3 
mg/kg of (1-ethoxy-N-(3-morpholino-5- oxadiazol-3-iumyl) methanimidate 
(molsidomine) were prepared based on the daily food intake measured for these animals. 
For in vivo miR treatments, 5 μg (every 3 days for a total of 4 consecutive injections) of 
miR-34a antagomiR in saline (50 μl) was intramuscularly injected into the right TA of 
dystrophic mice. The controlateral TA was injected with the same protocol with control 
antagomiR as negative control. Mice were sacrificed 4 days after the last intramuscular 
injection to avoid inflammatory infiltration. 
 
High resolution respirometry 
The respiratory chain capacity efficiency was determined by high-resolution respirometry 
(HRR) on permeabilized muscle fibers from 5 months wild type and dystrophic mice 
(standard diet or molsidomine treated). This technique allows to measure total 
mitochondrial VO2 and to suggest the role of each mitochondrial complex in the process. 
After cervical dislocation, diaphragm or tibialis anterior muscles were excised and placed 
into a Petri dish containing ice-cold biopsy preservation solution (BIOPS: 15 mM 
Phosphocreatin, 5.77 mM ATP, 6.56 mM MgCl2, 10 mM EGTA, 0.1 mM free Ca, 20 
mM imidazol, 20 mM taurin, 50 mM K-MES, 0.5 mM DTT),  
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The fibers were permeabilized by gentle agitation for 30 min at 4°C in solution 
supplemented with 50 μg/ml saponin. Fibers were washed in ice-cold respiration medium 
(see below) by agitation for 10 min and were kept in this medium until respirometric 
assay. 
The respiration rates of single fibers obtained from TA and Diaphragm were measured 
using two-channel titration injection respirometers (Oroboros, Instruments Oroboros, 
Innsbruck, Austria) at 37 °C in a respiration medium containing 0.5mM EGTA, 3mM 
MgCl2 60mM lactobionate, 20mM taurine, 10mM KH2PO4, 20mM HEPES, 110mM 
sucrose and 1 g/l of BSA (bovine serum albumin). Before each experiment the medium 
was equilibrated with air in the oxygraph chambers at 37°C until a stable signal was 
obtained for oxygen calibration.  
The software DatLab (Oroboros) was used for data acquisition and analysis. 
We placed fibers (1–3 mg wet weight) into the O2K oxygraph chambers and we added 
glutamate (10 mM), malate (2 mM) and ADP (2.5 mM) to obtain state 3 respiration. 
Then, we injected succinate (10 mM) to have an estimation of the entire OXPHOS 
capacity (CI+CII activity). Then, CII activity was measured by injecting rotenone 0.5 μM 
and inhibiting CI after convergent stimulation of CI+II. Finally, inhibition of CIII with 
antimycin A 2.5 μM and of CII with malonate 5 mM was followed by CIV stimulation 
with TMPD (N,N,N′,N′-tetramethyl-p-phenylenediamine) 0.5 mM and ascorbate 2 mM. 
Experiments were performed at 25 °C and all data were normalized to fiber weight or 
mtDNA content. 
 
DNA, RNA and protein extraction 
DNA Extraction: Total DNA was isolated from fresh-frozen muscles, heart, liver and 
brown adipose tissue (BAT) using the DNeasy Tissue Kit (Qiagen, Hilden, Germany) as 
described in the protocol provided by the manufacturer. After eluition in water, total DNA 
was quantified by the Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific). 
RNA Extraction: Total RNA was isolated from boath Tibialis Anterior and diaphragm 
using TRIzol reagent (Invitrogen, Life Technologies, Cergy, France) following the 
manufacturer's instructions. After solubilization in RNase-free water, total RNA was 
quantified by the Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific). First-
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strand cDNA was generated from 1 ug of total RNA using ImProm-II Reverse 
Transcription System (Promega).  
Protein Extraxtion: Tissue samples from TA and diaphragm muscles were homogenised 
in a lysis buffer containing 20mM Tris-HCl (pH 7.4), 10 mM EGTA, 150 mM NaCl, 1% 
Triton X-100, 10% glycerol, 1% SDS supplemented with a cocktail of protease and 
phosphatase inhibitors (Sigma, St. Louis, MO, USA). Samples were centrifuged at 1000 x 
g for 10 minutes at 4°C to discard cellular debris. Protein concentration was determined 
using the Micro BCA Protein Assay Kit (Thermo Scientific-Pierce Biotechnology, 
Rockford, IL), according to the manufacturer's protocol. 
 
Quantification of mtDNA copy number 
The mtDNA content was measured by real-time PCR normalizing the quantity of a not-
polymorphic mitochondrial gene (NADH dehydrogenase 1, ND1) with a single-copy 
nuclear gene (RNAse P). Real-time PCR was performed using the SYBR Green Supermix 
(Bio-Rad) on a Roche LightCycler 480 Instrument (Roche Diagnostics, Rotkreuz, 
Switzerland). For each assay, 10 ng of total DNA were analyzed in triplicate. Samples 
were analyzed using the Roche LightCycler 480 Software (release 1.5.0) and the second 
derivative maximum method. Specific sets of primer pairs, described in Table 1, were 
designed to hybridize to unique regions of the appropriate gene sequence. 
 orward Primer everse Primer 
RnaseP 
(DNA) 
 
5’-GAAGGCTCTGCGCGGACTCG-3’ 
 
5’-CGAGAGACCGGAATGGGGCCT-3’ 
ND1    
(DNA) 
 
5’-CCTATCACCCTTGCCATCAT-3’ 
 
5’-GAGGCTGTTGCTTGTGTGAC-3’ 
 
Tab.1: Primers used for quantification of mtDNA copy number 
 
Immunoblotting and antibodies 
Protein separation was performed following the standard protocol for western blotting. 
Samples were solubilized in Laemmli buffer, boiled 5 min at 100 °C and loaded on 4-20 
% polyacrylamide precast gels (Mini-PROTEAN TGXTM; Bio-Rad) immersed in 
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running buffer (Tris-base, SDS, glycin) (Gels were run at 300V). Proteins separated in the 
gel were transferred onto a nitrocellulose membrane using a Bio-Rad's Trans-Blot Turbo 
SystemTM (7 min at 2.5 A) using Bio-Rad Transfer packTM.  
The nitrocellulose membrane was blotted with Ponceau red, to determine the quality of 
the protein transfer. Then it was incubated for 1 hour at room temperature in a blocking 
buffer (TBS-T: Tris-buffered saline-Tween 20 (Tris-HCl, NaCl, Tween 20) and non fat 
dry milk 5%), to block the sites for unspecific binding of the antibodies to the membrane. 
Then, membrane was incubated with a primary antibody, specific for the protein of 
interest, and, after three washes in TBS-T, with a secondary anti-rabbit horseradish 
peroxidase (HRP)-conjugated antibody, both diluted in Blocking buffer for 1 hour each. 
After these incubations the membrane was rinsed with TBS-T 3x10 min. Detection of the 
antigen was performed with the system of HRP/Hydrogen Peroxide catalyzed oxidation 
of luminol in alkaline conditions using the Clarity Western ECL Substrate by Bio-Rad. 
The light produced by this enhanced chemiluminescent reaction was detected using 
CemiDocMP Imaging SystemTM. 
The membranes were probed using the following primary antibodies anti: phospho- 
AMPKα (Thr172) (2531), AMPKα (2532), obtained from Cell Signaling Technology 
(Billerica, MA, USA). Antibodies to LC3 (L7543) and p62 (P0067), BNIP3 (B7931) 
were from Sigma, antibodies to VDAC1 (ab15895) and mtCO1 (ab14705) were from 
Abcam and antibody to COX IV (A21348) was from Life Technologies. The secondary 
antibodies were from Bio-Rad (anti-rabbit and anti mouse Ab HRP-conjugated).  
 
Mitochondrial biogenesis induction through cold exposure 
A control group was kept at 23°C, while experimental groups were kept at 48°C for 24 or 
72 hours. Animals were sacrificed and tissues were dissected and collected immediately. 
 
Quantitative Real Time PCR 
Real-time PCR was performed using the SYBR Green Supermix (Bio-Rad) on a Roche 
LightCycler 480 Instrument (Roche Diagnostics, Rotkreuz, Switzerland), according to 
manufacturer’s recommended procedure. As shown in Table 2, a set of primer pairs were 
designed to hybridize to unique regions of the appropriate gene sequence. 
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All reactions were run as triplicates. The melt-curve analysis was performed at the end of 
each experiment to verify that a single product per primer pair was amplified. As to 
control experiments, gel electrophoresis was also performed to verify the specificity and 
size of the amplified qPCR products. 
Samples were analysed using the Roche LightCycler 480 Software (release 1.5.0) and the 
second derivative maximum method. The fold increase or decrease was determined 
relative to a control after normalising to the internal standard 36b4 through the use of the 
formula 2-ΔΔCT 195-196. 
 
 orward Primer Reverse Primer 
36b4 
(mRNA) 
 
5′-AGGATATGGGATTCGGTCTCTTC-3′ 
 
5′-TCATCCTGCTTAAGTGAACAAACT-3′ 
PGC1α 
(mRNA) 
 
5’-ACTATGAATCAAGCCACTACAGAC-3’ 
 
5’-TTCATCCCTCTTGAGCCTTTCG-3’ 
Nrf-1 
(mRNA) 
 
5’-ACAGATAGTCCTGTCTGGGGAAA-3’ 
 
5’-TGGTACATGCTCACAGGGATCT-3’ 
Tfam 
(mRNA) 
 
5’-AAGACCTCGTTCAGCATATAACATT-3’ 5’-TTTTCCAAGCCTCATTTACAAGC-3’ 
Sirt1 
(mRNA) 
 
5’-ACGGTATCTATGCTCGCCTTG-3’ 
 
5’-GACACAGAGACGGCTGGAAC-3’ 
CytB 
(mRNA) 
 
5’-CTTCGCTTTCCACTTCATCTTACC-3’ 
 
5’-TTGGGTTGTTTGATCCTGTTTCG-3’ 
MCAD 
(mRNA) 
 
5’-AGGGTTTAGTTTTGAGTTGACGG-3’ 
 
5’-CCCCGCTTTTGTCATATTCCG-3’ 
LCAD 
(mRNA) 
 
5’-TCTTTTCCTCGGAGCATGACA-3’ 
 
5’-GACCTCTCTACTCACTTCTCCAG-3’ 
PDK4 
(mRNA) 
 
5’-AGGGAGGTCGAGCTGTTCTC-3’ 
 
5’-GGAGTGTTCACTAAGCGGTCA-3’ 
 
Tab.2: Primers used for quantitative RT real-time PCR analyses 
 
Muscle mitochondria isolation 
Muscles were minced with scissors in 1ml of ATP medium (100 mM KCl, 50 mM TRIS 
HCl ph 6.8, 5 mM MgCl2, 1.8 mM ATP, 1 mM EDTA) + Collagenase type II 0.1% in a 2 
ml tube and then digested for 10 minutes at 37°C under strong agitation. 
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After centrifugation at 380 x g for 5 min, pellet was washed twice with ATP medium, 
resuspended in 700 μl of ATP medium and homogenized with ultraturrax. 
Then we centrifugated at 380 x g for 5 min, 4°C in order to pellet nuclei, myofibrillar 
components and tissue fragments. Supernatant was collected and spun twice at 10000 x g. 
The final mitochondrial pellet was washed twice and suspended slowly into Mito 
Resuspension Buffer (225 mM Sucrose, 44mM KH2PO4, 12.5 mM Tris Acetate ph 7.75, 
6 mM EDTA).  
 
ATP production from isolated mitochondria 
ATP concentration was determined using the luciferin-luciferase method. Briefly, isolated 
mitochondria were resuspended in Mito Resuspension Buffer. They were then washed by 
adding 1ml of buffer-A (150 mMKCl, 25 mM Tris HCl, 2 mM EDTA, 0.1 % BSA, 0.1 
mM MgCl2, 10 mM KH2PO4) and pelletted at 10000 × g. The pellets were resuspended in 
160μl of buffer-A and plated in 96 wells in triplicate. The samples were treated with 30μl 
of a mix containing 1mM malate, 1mM pyruvate, 0.1mM ADP (Sigma), 10μl buffer-B 
(containing 0.8mM luciferin and 20mg/ml luciferase in 0.5M Tris-acetate (pH 7.75)) and 
either 1μg/ml oligomycin to assess OXPHOS ATP. ATP was measured using a GloMax 
luminometer (Promega, Madison, WI, USA). 
 
Immunofluorescence assay 
The animals were killed by cervical dislocation, and TA or diaphragm muscles were 
dissected and immediately frozen in liquid N2-cooled isopentane. 
Frozen 10μm cross-sections of muscle were fixed with paraformaldehyde 4% for 10 min 
at 4 °C, blocked for 30 min with 2% goat serum, 0,5 % BSA-PBS at room temperature 
and then incubated with primary antibodies directed to BA-D5 for type 1 MHC and to 
SC71 for type 2a (1:400, Developmental Studies Hybridoma Bank). All primary 
antibodies were diluted in PBS, 2% goat serum, 0,5 % BSA and incubated at room 
temperature for 2 hours. After incubation with the appropriate fluorescent-labeled 
secondary antibodies (goat anti-mouse IgG2b conjugated to AlexaFluor 568 for BA-D5, 
goat anti-mouse IgG1 conjugated to AlexaFluor 488 for SC71, all from 
Invitrogen/Molecular Probes), nuclei were counterstained with Hoechst 33342 (Molecular 
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Probes, Life Technologies) and slides were finally mounted with the ProLong Gold 
antifade reagent (Invitrogen, Life Technologies). Stained tissues were photographed with 
a LEICA CTR4000 fluorescence microscope. 
 
SDH staining 
SDH staining was performed for 30 min at 37°C using succinate as a substrate and nitro 
blue tetrazolium as a redox indicator. Criosections were then washed in distilled water (3 
changes), and fixed in neutral formalin 10% for 10 minutes. After 10 minutes in 15% 
ethanol sections were washed, mounted with mounting medium (glycerol 80% in PBS) 
and visualized using a LEICA CTR4000 microscope. 
The darkest staining fibers (type I and II) were counted and their percentage of total 
number of fibers was calculated (150–200 total fibers/image, 5 images/mouse, 5 mice/ 
experimental group). 
 
 
Fluorescent and phase-contrast image acquisition and manipulation 
Fluorescent and phase-contrast images were taken on microscopes (Leica DMI4000 B 
automated inverted microscope; lenses: HCX PL FLUOTAR × 10/0.30, HI PLAN I × 
40/0.59 and HCX PL FLUOTAR × 100/1.30). Images were acquired using a DFC490 
digital colour camera (Leica Microscopy Systems, Heerbrugg, Switzerland) and the 
acquisition software LAS AF (Leica Microscopy Systems). Images were assembled in 
panels using Photoshop 7.0 (Abobe System Software, Dublin, Ireland). 
 
PGC-1α acetylation assay 
We analyzed PGC-1α acetylation in tibialis anterior and diaphragm muscles by 
immunoprecipitation of PGC-1α from 500 μg of protein extract with antibodies to PGC-
1α (Santa Cruz, sc-13067, 2 μg per sample) followed by western blot analysis using 
antibodies to acetyl-lysine (1:2,000, Cell Signaling 9441). 
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Quantification of miR expression 
The total RNA including the miR fractions was isolated using TRIzol reagent (Invitrogen, 
Life Technologies, Cergy, France) following the manufacturer's instructions.  
The quantification of miR-34a was performed using Taqman assays for miR (Applied 
Biosystems) and Taqman Universal Master Mix (Applied Biosystems). miR levels were 
quantified using miR-U6B as the housekeeping miR.  
 
 
Statistical analysis 
Values were expressed as means ± standard error of the mean (S.E.M.). The statistical 
significance of the differences between means was assessed by independent Student’s t-
test or by one-way ANOVA followed by the Bonferroni post-test to determine which 
groups were significantly different from the others. A probability of <5% (P<0.05) was 
considered to be significant. 
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RESULTS 
 
a-Sarcoglycan null mice have a lower mitochondrial content and capacity 
 
Mitochondrial function was assessed as function of oxygen consumption in permeabilized 
muscle fibers from Tibialis Anterior (TA) and diaphragm (DP) of 5 month old a-SG null 
mice and compared to the respective age-matched wild-type mice. In both dystrophic 
muscles the respiratory rates, expressed per tissue wet weight and measured with 
substrates targeting complex I (CI), complex II (CII) and complex IV (CIV), were 
significant reduced (Fig. 1A). Of interest, real-time quantitative PCR analysis of 
mitochondrial DNA (mtDNA) revealed a marked reduction of mitochondrial content in 
both a-SG null muscles (Fig. B). We then expressed the respiratory rates relative to 
mtDNA copy number and we abolished the differences observed both in TA and 
diaphragm of dystrophic mice, suggesting that mitochondrial content could be the major 
determinant of the lower oxidative capacity of a-SG null muscles. However these data 
also indicate a decreased capacity of the entire respiratory chain, rather than a deficiency 
of a single complex, but this point will need further investigation, measuring the 
respiratory capacity of equal amount of isolated mitochondria. This allows us to 
definitively understand whether dystrophic muscle fibers display lower respiratory 
function associated with a decreased in mitochondrial content. Consistent with the 
reduced mtDNA content, the expression of both nuclear encoded mitochondrial proteins 
(VDAC and COX IV) and mitochondrial encoded protein mtCO1 were significantly 
lower in a-SG null mice as assessed by immunoblotting on whole TA and diaphragm 
homogenates and compared to age-matched wild-type.  
Altogether these findings indicate that mitochondrial mass is significantly decreased in 
TA and diaphragm of dystrophic a-SG null mice, probably accounting for their reduced 
OxPhos capacity. 
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Figure 1: a-Sarcoglycan null mice have a lower mitochondrial content and capacity 
A) Mitochondrial respiration in permeabilized TA and diaphragm muscle fibers from a-SG null and WT 
mice (n = 8 per genotype).  B) Mitochondrial DNA (mtDNA) content (n = 8 per genotype). C) 
Mitochondrial respiration in permeabilized TA and diaphragm muscles fibers normalized for mtDNA copy 
number. D) Western blot analysis of mitochondrial proteins (VDAC; mtCO1 and COX IV) in TA and 
diaphragm homogenates from WT and a-SG null mice (n= 6 per genotype). The graph shows the 
densitometric values normalized on the total protein content (right panel) ± SEM. 
 
 
 
The low mitochondrial content is a muscle specific defect in a-SG null mice 
and correlates with the disease progression 
 
To understand whether there is a direct link between the genetic defect (the lack of alpha 
sarcoglycan from dystrophin complex at the sarcolemma level) and the mitochondrial 
content we assessed by qPCR the mtDNA copy number in different tissues and we found 
out that the deficiency in mtDNA content was only present in skeletal muscles (tibialis 
anterior and diaphragm), but not in heart, liver and brown adipose tissue (BAT) (Fig. 2A-
B-C-D-E), suggesting that tissues not directly involved in the pathology do not show a 
mitochondrial damage. 
We also analyzed mitochondrial content in muscle during the development (1.5, 3 and 5 
months) of wild-type and a-SG null mice and we observed a marked increase in 
mitochondrial mass in both TA and diaphragm, between 3 and 5 months of age in wild-
type mice. Conversely, in both muscles of dystrophic mice we did not observe any 
increase in mitochondrial mass during the development.  
In particular, diaphragm from a-SG null mice showed differences in mitochondrial 
content starting from 3 months of age, while a-SG-/- TA, at each time considered, 
exhibited a significant lower mitochondrial content compared to wild-type (Fig. 2F-G). 
These data indicate that the mitochondrial content defect correlates with the progression 
of the disease and the worsening of the muscular phenotype with a much higher 
impairment at 5 months of age compared to younger mice. 
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Figure 2: The low mitochondrial content is a muscle specific defect in alpha-sarcoglycan null 
mice and correlates with the disease progression 
A-B-C-D-E) qPCR analysis for mtDNA content in different tissues (n = 5 per genotype). Values are 
expressed as mean ± SEM. F-G) Mitochondrial content in TA and diaphragm during development (1.5- 3 
and 5 months of age). Asterisks indicate statistical significance between WT and a-SG -/- mice at each point 
considered. Values are expressed as mean ± SEM (n = 4 or 5 per genotype). 
 
 
 
In alpha-sarcoglycan null mice the reduced mitochondrial content is the result 
of induction of mitophagy and repression of mitochondrial biogenesis 
 
Mitochondrial abundance is directly correlated to the coupling between mitochondrial 
biogenesis and mitochondrial degradation by autophagy.  
Autophagy is a self-digestion process that mediates the selective clearance of cytoplasmic 
components, such as damaged mitochondria (mitophagy) that could otherwise become 
deleterious. 
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To explore whether autophagy could be involved in the decreasing of mitochondrial mass 
we measured different markers. Compared to wild-type mice, TA and diaphragm from 5 
months old a-SG null mice showed a significant increase in the lipidated form of 
microtubule-associated protein-1 light chain 3 (LC3)-II, which is a common marker of 
autophagy 197. In agreement, BCL-2/adenovirus E1B–interacting protein-3 (Bnip3), a 
protein recognized to have a key role in the autophagic removal of mitochondria 198-199, 
was induced in TA and diaphragm of a-SG null mice. Finally p62, a cargo protein known 
to be incorporated into autophagosomes 200 and degraded, decreased in both dystrophic 
muscles (Fig. 3A). Taken together these results provide clear evidence that mitophagy 
process could be responsible for with the reduction of mitochondrial content likely in 
order to supply energy. 
However, since mitochondrial biogenesis is the other main process directly regulating 
mitochondrial abundance, we analyzed the relative expression of the master genes 
involved in the mitochondrial biogenesis pathway. Interestingly the mRNA level of the 
master gene peroxisome proliferator–activated receptor γ coactivator 1α (PGC-1α), as the 
mRNA levels of nuclear respiratory factor 1 (Nrf1) and mitochondrial transcription factor 
A (Tfam), were significantly down-regulated in dystrophic muscles. Also the expression 
level of the mitochondrial gene Cytochrome B (CytB) was significantly decreased in a-
SG null mice, suggesting that also the biogenetic process could be repressed in dystrophic 
condition (Fig. 3B). 
To better clarify this point, we wondered whether mitochondrial biogenesis could be 
enhanced by a well-known inducer such as cold exposure, comparing wild-type and a-SG 
null mice at 5 months of age. After 72h of cold exposure, mitochondrial content 
significantly increases in wild-type TA and diaphragm, whereas it was unchanged in a-SG 
null muscles (Fig. 3D). In agreement with these results, we measured the mRNA levels of 
several genes involved in the biogenetic process and as expected, PGC-1α, Nrf1, Tfam 
and Cyt B increased in wild-type TA and diaphragm after 24h of cold exposure, but not in 
a-SG null mice (Fig. 3C). 
Overall our data indicate that a-SG null muscles display a defective mitochondrial 
biogenesis process that in combination with the increased mitophagy explains the marked 
reduction of mitochondrial mass a-SG null mice. 
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Figure 3: In alpha-sarcoglycan null mice the reduced mitochondrial content is the result of 
induction of mitophagy and repression of mitochondrial biogenesis 
A) Representative immunoblot of muscle homogenates from WT and a-SG null mice (50 μg per 
lane). The graphs shows the densitometric values of p62 and Bnip3 normalized on the total 
protein content (right panel) ± SEM. Values for LC3 represent the ratio LC3II/LC3I ± SEM (n = 6 
per genotype). B) RTqPCR analysis of mitochondrial biogenesis pathway genes in TA and 
diaphgram. Values are expressed as mean ± SEM (n = 8) C) RTqPCR analysis of mitochondrial 
biogenesis pathway genes in TA and diaphgram after 24 hours of could exposure (4°C). The 
graphs represent the fold induction of stimulated mice over basal condition. (n= 5 per genotype) 
D) qPCR analysis for mtDNA content after 72 hours of cold exposure. The graphs represent the 
fold induction of stimulated mice over basal condition. (n= 5 per genotype). 
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NO-donor Molsidomine modulates mitochondrial function in a-SG null mice 
 
In a previous work we demonstrated the positive action of long-term treatment (at 5 and 9 
months) with molsidomine on muscle function and recovery in the a-SG null mice. The 
NO-donor molsidomine is converted in vivo to its active metabolite SIN-1 and enhances 
significantly voluntary and forced motor activities, indicating that functional recovery of 
the muscle has taken place 1. 
Since improved muscle function and endurance can result from activation of slow 
oxidative program 201 we measured whether molsidomine treatment of a-SG null mice for 
5 months, could affect mitochondrial functions improving OxPhos capacity. 
Permeabilized muscles fibers from TA and diaphragm of treated a-SG null mice showed 
an increased respiratory capacity expressed per tissue wet weight and measured with 
substrates targeting complex I (CI),complex II (CII) and complex IV (CIV), compared to 
untreated a-SG null mice (Fig. 4A). In agreement with this, mitochondria from TA and 
diaphragm of treated a-SG null mice supplemented with CI substrates, produced more 
ATP over the time compared to mitochondria from untreated dystrophic mice (Fig. 4B). 
This shift toward more oxidative metabolism in molsidomine-treated a-SG null mice 
occurred in absence of changes in mitochondrial density in both muscles assessed by 
qPCR for mtDNA copy number (Fig.4C). 
Next, we evaluated whether molsidomine could promote fiber type switching, assessing 
the contractile phenotype of muscle fibers. We quantified two markers of slow-twitch 
fibers (myosin heavy chains type I and type IIa) by immunofluorescence in TA and we 
observed a positive trend for the expression of type I, and a significant increase for type 
IIa myosin heavy chains (MyHC) in molsidomine-treated a-SG null mice. In addition the 
succinate dehydrogenase (SDH) staining revealed that the proportion of blue-stained 
oxidative fibres was higher in TA of treated a-SG null mice compared to untreated 
dystrophic mice (Fig. 4D). Interestingly this switch correlated with an increased 
expression of genes which promote the use of fatty acid over glucose; for instance 
molsidomine treatment enhanced the expression of medium and long-chain acyl- CoA 
dehydrogenases (MCAD and LCAD) and pyruvate dehydrogenase kinase 4 (PDK4) in 
both TA and diaphragm of a-SG null mice. 
Therefore molsidomine induces a switch toward more oxidative muscle fibers mostly 
triggering fatty acid oxidation rather than improving mitochondrial function per se. 
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Figure 4: NO-donor Molsidomine modulates mitochondrial function in a-SG null mice 
A) Mitochondrial respiration in permeabilized TA and diaphragm muscle fibers from a-SG null mice 
untreated or treated with molsidomine (n = 8 per group).  B) OxPhos ATP production over the time (10 
minutes) in mitochondria isolated from both TA and diaphragm of dystrophic mice (treated or untreated 
with molsidomine) (n = 5 per group). C) Mitochondrial DNA content after molsidomine treatment in 
dystrophic mice (n = 8 per group). D) Histological analysis of a-SG KO tibialis anterior before and after 
molsidomine diet. Representative MyhCs immunostaining (upper panel) and SDH staining (lower panel). 
MyhC I (red) and MyhC IIa (green) were counted and their percentage of total number of fibers was 
calculated in the graph. Values are expressed as mean ±SEM. (n= 6 per group) E) RTqPCR analysis of fatty 
acid oxidation pathway genes in TA and diaphgram. Values are expressed as mean ± SEM (n = 8). 
 
 
 
Molsidomine affects muscle metabolism through Sirt1 modulation 
 
We aimed to gain insight into the molecular mechanism of nitric oxide action on 
mitochondrial metabolism observed in a-SG null mice. It has been reported that PGC-1α 
has a critical role in the control of mitochondrial OxPhos capacity and this cofactor is able 
to functionally convert fast-twitch fibers into more oxidative slow twitch fibers 160,202 , 
coupling the metabolism with the contractile apparatus of muscle fibers, therefore we 
examined whether it is involved in the effects of molsidomine in a-SG null muscles. 
PGC-1α is known to be tightly controlled at transcriptional and posttranscriptional levels 
and in our system the mRNA levels of PGC-1α did not change after 5 months of 
molsidomine treatment in a-SG null mice, in both TA and diaphragm (Fig. 5A). 
Posttranslational modifications such as acetylation negatively correlate with PGC-1α 
activation and when we carried out an immunoprecipitation assay to evaluate the 
aceylation status of the protein we found out high levels of acetylated form of PGC-1α in 
a-SG null muscles compared to wild-type mice. After molsidomine treatment PGC-1α 
acetylation levels decreased at basal level in both TA and diaphragm, leading to enhanced 
protein activity (Fig. 5B and 5C). 
PGC-1α is an established substrate of Sirt1, in particular Sirt1 associates with PGC-1α 
triggering its deacetylation 203 and considering our results we assessed Sirt1 in our model. 
We measured Sirt1 mRNA levels in TA and diaphragm comparing molsidomine treated 
and untreated a-SG null mice and we observed a significant increase of Sirt1 expression 
after molsidomine treatment in both muscles (Fig. 5D), likely suggesting Sirt1 as target of 
NO action, thus modulating PGC-1α activation and mitochondrial function. 
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Figure 5: Molsidomine affects muscle metabolism through Sirt1 modulation 
A) RTqPCR analysis of PGC-1α on mRNA extracted from TA and diaphgram of dystrophic mice 
(untreated or treated with molsidomine). Values are expressed as mean ± SEM (n = 8 per group).  B-C) 
PGC-1α acetylation. Immunoprecipitation followed by western blotting analysis showing acetylation levels 
of PGC-1α in lysine residues compared to total PGC-1α in both TA and diaphragm (C). The graph 
represents the quantification as mean ± SEM in WT, a-SG-/- and a-SG-/- mice after molsidomine treatment. 
(n = 4 per group). D) RTqPCR analysis of Sirt1 on mRNA extracted from TA and diaphgram of WT mice 
and dystrophic mice (before and after molsidomine treatment).  
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Sirt1 modulation by nitric oxide is independent on miR-34a and dependent on 
AMPK 
 
Published data show that Sirt1 expression can be modulated by microRNAs that can bind 
Sirt1 mRNA preventing its translation. In particular miR-34a negatively regulates Sirt-1 
expression, increasing acetylation of its target proteins 204. To test whether an aberrant 
expression of miR-34a correlated with a repression of Sirt1 in a-SG null TA and 
diaphragm, we determined the expression of miR-34a in both muscles but we found out a 
significant increase in a-SG-/- mice compared to wild type animals only in TA (Fig. 6A), 
whereas in diaphragm there was no difference between the two experimental groups 
(Fig.6B). Moreover molsidomine was not able to significantly decrease the miR 
expression in dystrophic muscles, indicating that the molsidomine-dependent increase of 
Sirt1 expression and function was not due to the modulation of miR-34a by nitric oxide 
(Fig. 6A and 6B).  
To definitively exclude the role of miR-34a as a negative regulator of Sirt1 expression in 
dystrophic muscles, miR-34a levels were down-regulated by injecting the specific 
antagomiR intramuscular into the right TA (of 5 months old) a-SG null mice and Sirt1 
mRNA level was examined afterward. After 4 injections of antagomiR, qPCR analysis 
demonstrated that miR-34a levels were diminished by 50% in right TA compared to the 
controlateral one injected with scramble oligomiR (Scramble) (Fig. 6C). Nevertheless 
antagomiR injection was not able to modulate Sirt1 expression, confirming that miR-34a 
is not responsible for the modulation of Sitr1 expression in a-SG null mice (Fig. 6D). 
However adenosine monophosphate–activated protein kinase (AMPK) has been described 
as important activator of Sirt1 expression 205 and function 206. Furthermore AMPK is 
known to be activated by NO in endothelial cells 207 thus we can hypothesize a role of 
AMPK in the NO-dependent Sirt1 activation in a-SG null mice. 
Since the phosphorylation of threonine 172 in the α-subunit strongly correlates with the 
AMPK activity 208 we analyzed the phosphorilation status of AMPK in Molsidomine-
treated a-SG-/- mice compared to untreated mice. 
We found out a significant increase in AMPK phosphorilation after molsidomine 
treatment, suggesting that AMPK was the principal mediator of the NO-dependent effects 
on fiber type switching, improving mitochondrial function in a-SG null mice (Fig. 6E). 
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Figure 6: Sirt-1 modulation by nitric oxide is independent on miR-34a and dependent on 
AMPK 
A-B) miR-34a expression levels analyzed in TA and diaphragm muscles of WT, a-SG-/- and a-SG-/- treated 
mice by quantitative PCR. Values of a-SG-/- mice (from untreated or form treated mice) were both 
normalized with respect to values of aged-matched WT mice (means ± SEM; n = 9 for each group). C-D) 
TA muscles of a-SG-/- mice were injected with antagomir for miR-34a (Ant-miR-34a) or with Scramble 
oligomiR (Scramble). qPCR analysis for miR expression (C) and for Sirt1 expression (D). Values are 
expressed as mean ± SEM (n = 9). E) Representative immunoblot for p-AMPK (Thr172) and total AMPK 
in TA and diaphragm of WT and a-SG KO mice. The graph shows the ratio pAMPK/ total AMPK and the 
values are expressed as mean ± SEM (n = 6). 
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In this study we describe, for the first time, abnormalities in mitochondrial content and 
function in skeletal muscles of a mouse model of Limb Girdle muscular dystrophy 2D.  
Mitochondrial abnormalities have been reported for several different types of muscular 
dystrophy, even those not caused by mutations in mitochondrial DNA or in genes coding 
for mitochondrial proteins. The most relevant to our study is the documentation of a 
general metabolic crisis in dystrophic muscles of Duchenne and Limb Girdle 2D patients, 
with large scale down-regulation of nuclear-encoded mitochondrial gene expression 186. 
In this case the mutated genes did not have a direct or obvious involvement in the 
mitochondrial metabolism, indicating that mitochondrial abnormalities could be 
considered as a secondary feature of many different types of muscular dystrophy. 
Taking into advantage by the utilization of a mouse model of LGMD-2D (the a-
sarcoglycan null mouse), we demonstrate a severe reduction the in OxPhos capacity of 
both tibialis anterior and diaphragm muscles of dystrophic compared to the respective 
age-matched wild-type mice. Since both muscles of a-sarcoglycan null mice show a 
reduced mitochondrial content than wild-type animals we hypothesize that the lower 
mitochondrial mass is the major determinant for the reduced OxPhos capacity of these 
muscles. This idea is supported by the fact that when we normalize the respiratory rates 
relative to mtDNA, instead of tissue wet weight, we eliminate the differences observed 
both in TA and diaphragm. However, to definitively exclude any defect in the respiratory 
chain complexes it will be necessary the analysis of oxygen consumption starting from 
equal amounts of isolated muscle mitochondria. 
Taking into account the data reported above we decided to focalize our attention on the 
severe mitochondria depletion observed in the dystrophic model, and we observed an 
important correlation between the progression of the disease and the mitochondrial 
content that progressively decrease in a tissue specific manner. 
It has been well established that mitochondrial abundance is directly regulated by two 
opposite pathways that cooperate to maintain an appropriate mitochondrial mass. These 
pathways are mitochondrial biogenesis and mitochondrial degradation by autophagy.  
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In spite of many papers that have documented an autophagy impairment in different 
models of muscular dystrophy (DMD, UCMD and Emery-Dreyfuss muscular dystrophy 
EDMD) 197,209-210, we demonstrate an activation of mitophagy in a-SG-/-, as established by 
the induction of BNIP3 that is a clear marker of autophagic removal of mitochondria. 
This data, together with the analysis of respiratory chain function, support the idea that 
even if they are few, mitochondria of knock-out muscles are still functional and that up-
regulation of mitophagy is a mechanism aimed to preserve their function. 
But increased autophagy is not the only mechanism responsible for the low mitochondrial 
content in a-SG null mice. We also show a persistent impairment of the 
mitochondriogenesis pathway driven by PGC-1α co-activator in muscular dystrophy. The 
mRNA expression levels of all the genes involved in mitochondrial biogenesis are in fact 
reduced in a-SG null  muscles and not even a well known activator of the pathway, such 
as cold exposure, is able to stimulate the process in knock-out mice as instead occurs in 
wild-type animals.  
Taking into account that nitric oxide has been described as an important regulator of 
mitochondrial biogenesis in mammals 167 and that NO donors have been explored as new 
therapeutics for muscular dystrophy, we treated dystrophic mice with the NO-donor 
molsidomine to evaluate a possible impact on mitochondrial metabolism. Recent papers 
have demonstrated the ability of the NO-donor molsidomine to ameliorate the dystrophic 
phenotype in mouse models of DMD and LGMD, acting at different stages. The drug was 
able to stimulate satellite cells proliferation and self-renewal ability 1, to modulate the 
innate inflammatory response 103 and to regulate fibro-adipogenic precursors (FAPs) fate 
through inhibition of their differentiation into adipocytes 102, but the role of molsidomine 
on mitochondrial metabolism have not been investigated yet. 
Surprisingly, our data show that NO-donor molsidomine fails to induce mitochondrial 
biogenesis but exerts a beneficial effect on muscle metabolism stimulating a switch 
toward more oxidative muscle fibers that are more resistant to contraction-induced 
damage. In particular treated mice show an increased respiratory capacity associated with 
increased of oxidative ATP production, compared to untreated controls both in absence of 
induction of mitochondrial biogenesis. The analysis of fiber type composition, by 
immunofluorescence for myosin heavy chains and by SDH staining, demonstrates that 
NO treatment triggers a fiber switch toward more oxidative phenotype. Our data are 
supported by several papers in which a fast to slow fiber type shift ameliorates the 
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dystrophic phenotype and therefore can be considered a rescue mechanism and a potential 
target for therapeutic intervention 201,211. 
Unlike the studies mentioned above, our drug promotes the shift toward an oxidative 
phenotype controlling the oxidation of fatty acids rather than stimulating the 
mitochondrial functionality per se. Molsidomine induces the mRNA expression of 
MCAD, LCAD and PDK4, all genes promoting the flux of fatty acid and their utilization 
to produce energy. 
It has been demonstrated that PGC-1α deacetylation, but not its upregulation, is required 
for activation of mitochondrial fatty acid oxidation genes program 155 so we hypothesize a 
role of molsidomine in deacetylating PGC-1α thus driving the oxidative fibers switch. 
At the molecular level we find out that Molsidomine modulates PGC-1α not directly 
increasing its mRNA and expression, but modifying its acetylation status and activity. 
Our data indeed demonstrates that nitric oxide primarily regulates the expression level of 
the deacetylase Sirt1 which in turn controls PGC-1α acetylation status. 
Sirt1 is an evolutionarily conserved NAD+-dependent deacetylase that controls both 
energy homeostasis and metabolic adaptations 212 and functions to counteract metabolic 
and age-related disease. Of interest we demonstrate an up-regulation of mRNA level of 
Sirt1 in molsidomine treated muscles. Despite the extensive studies of Sirt1 downstream 
effectors, the upstream regulatory network is relatively less understood. A very important 
mechanism regulating Sirt1 expression is the control by microRNAs and it has been 
described that miRNA-34a binds to the 3’-untranslated region in its mRNA and represses 
its translation 204. Nevertheless when we assess for miR-34a deregulation in our model, 
we find out the absence of any NO-dependent control of miR-34a expression, furthermore 
in vivo the down-regulation of miR-34a does not have any effect in the modulation of 
Sirt1 expression. 
Looking for other modulators of Sirt1 expression, we pay particular attention on AMPK 
activity since it has been published that a chronic AMPK activation was able to drive the 
slow, oxidative myogenic program, triggering beneficial adaptations in mdx mouse model 
201. AMPK is an energy sensor that is activated when the cellular ratio of AMP to ATP 
increased 213 and it is also known to be activated by NO in endothelial cells 207. Also, 
AMPK has been described as an important activator of Sirt1 expression 205 and function 
206. Our results show a significant increase of AMPK phosphorilation after molsidomine 
treatment, identifying AMPK as the target of NO thus increasing Sirt1 expression. 
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In agreement with a very recent paper that demonstrated how Sirt1 over-expression in 
muscle could reverse the dystrophic phenotype of mdx mice 214, our data suggest that the 
NO-based therapy with molsidomine is a pharmacological approach that combine the 
multiple beneficial effect already described on different cell populations to a prominent 
action on muscle metabolism, inducing a therapeutic fiber switch toward a more oxidative 
types. Improving oxidative capacity nitric oxide is able to counteract the low 
mitochondrial content and the persistent impairment of mitochondrial biogenesis in 
dystrophic muscles, ameliorating the pathological phenotype of a-SG null mice.  
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